<SEC-DOCUMENT>0001493152-24-047143.txt : 20241121
<SEC-HEADER>0001493152-24-047143.hdr.sgml : 20241121
<ACCEPTANCE-DATETIME>20241121161023
ACCESSION NUMBER:		0001493152-24-047143
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20241118
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241121
DATE AS OF CHANGE:		20241121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Qualigen Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37428
		FILM NUMBER:		241484462

	BUSINESS ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011
		BUSINESS PHONE:		(760) 918-9165

	MAIL ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RITTER PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090402
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:QLGN="http://qlgntx.com/20241118">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_QLGN_qlgntx.com_20241118 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20241118_20241118 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001460702 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000004" name="dei:EntityCentralIndexKey">0001460702</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="qlgn-20241118.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-18</xbrli:startDate>
        <xbrli:endDate>2024-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_906_edei--DocumentType_c20241118__20241118_zcGLUKYQwP58"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_901_edei--DocumentPeriodEndDate_c20241118__20241118_zhQNs0Klebw2"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 18, 2024</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20241118__20241118_zwQ3ZvtkwEQ1"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000011" name="dei:EntityRegistrantName">Qualigen
Therapeutics, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20241118__20241118_zYyFTVuZyVSi"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20241118__20241118_zPXhuJbbncUi"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000013" name="dei:EntityFileNumber">001-37428</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20241118__20241118_zjsnJOgmPVkg"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-3474527</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_900_edei--EntityAddressAddressLine1_c20241118__20241118_zm4nYlJbHhHf"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000015" name="dei:EntityAddressAddressLine1">5857
Owens Avenue</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20241118__20241118_zCOZOA2TkDM5"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressCityOrTown_c20241118__20241118_zwGNOYhAA3w4"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000017" name="dei:EntityAddressCityOrTown">Carlsbad</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20241118__20241118_z4bi4VWMaxLb"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20241118__20241118_zhdHqhQQRNVf"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000019" name="dei:EntityAddressPostalZipCode">92008</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_909_edei--CityAreaCode_c20241118__20241118_zqS2hPoQrnua"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000020" name="dei:CityAreaCode">(760)</ix:nonNumeric></span>
<span id="xdx_90D_edei--LocalPhoneNumber_c20241118__20241118_zk8UeSsOxprc"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000021" name="dei:LocalPhoneNumber">452-8111</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">n/a</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--WrittenCommunications_c20241118__20241118_zNJ9rsi7Ycpb"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SolicitingMaterial_c20241118__20241118_zPd2NV8Dsb76"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20241118__20241118_zc08wGRVyP6d"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20241118__20241118_zOLO2bcXioA6"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20241118__20241118_zHmqmygZEgRe"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value $.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20241118__20241118_zo4H8HPcKxH2"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000027" name="dei:TradingSymbol">QLGN</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_904_edei--SecurityExchangeName_c20241118__20241118_zm6r907iEfsa"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market of The Nasdaq Stock Market LLC</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (&#167;230.405 of this
chapter) or Rule 12b-2 of the Exchange Act (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20241118__20241118_zdTD8mptMShg"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Item
1.01&#160;Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Securities
Purchase Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Securities Purchase
Agreement&#8221;) on November 18, 2024 with certain institutional investors (the &#8220;Investors&#8221;). Pursuant to the Securities
Purchase Agreement, the Company agreed to sell and issue shares of Qualigen&#8217;s newly designated Series A-2 Preferred Stock, par
value $0.001 per share (the &#8220;Qualigen Series A-2 Preferred Stock&#8221;), in a private placement transaction (the &#8220;Private
Placement&#8221;). The closing of the Private Placement was on November 20, 2024. The Company sold and issued to the Investor 5,100 shares
of Qualigen Series A-2 Preferred Stock at a purchase price of $1,000 per share, for an aggregate purchase price of $5.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Each
share of Qualigen Series A-2 Preferred Stock was, at any time at the option of the holder, convertible into a number of shares of the
Company&#8217;s common stock equal to $1,000 shares divided by a conversion price initially equal to $3.64, subject to adjustment for
any stock splits, stock dividends and similar events and also subject to &#8220;ratchet&#8221; antidilution adjustment (subject to certain
customary exceptions), provided that any conversion of Qualigen Series A-2 Preferred Stock by a holder into shares of the Company&#8217;s
common stock would be prohibited if, as a result of such conversion, the holder, together with its affiliates and any other person or
entity whose beneficial ownership of the common stock would be aggregated with such holder&#8217;s for purposes of Section 13(d) of the
Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the total number of shares of the the Company&#8217;s
common stock issued and outstanding after giving effect to such conversion. Upon written notice to the Company, the holder could from
time to time increase or decrease such limitation to any other percentage not in excess of 9.99% specified in such notice. Each share
of Qualigen Series A-2 Preferred Stock was entitled to a preference of $1,000 per share upon liquidation of the Company. Without consent
of the holders of at least 67% of the Qualigen Series A-2 Preferred Stock, The Company could not amend its charter documents to materially
and adversely affect the rights of the Qualigen Series A-2 Preferred Stock, repurchase certain junior securities of the Company, pay
cash dividends on junior securities of he Company or (unless it is at arm&#8217;s-length and is approved by a majority of the Company&#8217;s
disinterested directors) enter into a material transaction with an affiliate of the Company.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing, the Consulting Agreement (the &#8220;IR Agency Consulting Agreement&#8221;) dated October 9, 2024, between the Company and
IR Agency, LLC (&#8220;IR Agency&#8221;), a provider of investor relations services, will become effective. Pursuant to the terms of
the agreement, $800,000 of the proceeds will be paid to IR Agency. A copy of the IR Agency Consulting Agreement is attached as Exhibit
10.32 to the Form S-1 filed by the Company on October 24, 2024 (File No. 333-282820) and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding summary does not purport to be complete and is qualified in its entirety by reference to the Securities Purchase Agreement
for the Private Placement and the Certificate of Designation for the Qualigen Series A-2 Preferred Stock, copies of which are attached
hereto as Exhibit 3.1 and Exhibit 3.2, respectively, and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Placement Securities Purchase Agreement has been included as an Exhibit to this Current Report on Form 8-K to provide investors
and stockholders with information regarding its terms. It is not intended to provide any other factual information about the Company
or the parties thereto. The Private Placement Securities Purchase Agreement contains representations and warranties that the parties
thereto made to, and solely for the benefit of, each other. The assertions embodied in such representations and warranties are qualified
by information contained in the confidential disclosure schedules that each may have delivered to the other party in connection with
signing the Private Placement Securities Purchase Agreement. Accordingly, investors and stockholders should not rely on such representations
and warranties as characterizations of the actual state of facts or circumstances, since they were only made as of the date of the Private
Placement Securities Purchase Agreement and are modified in important part by the underlying disclosure schedules. Moreover, information
concerning the subject matter of such representations and warranties may change after the date of the Private Placement Securities Purchase
Agreement, which subsequent information may or may not be fully reflected in the Company&#8217;s public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities described above were not registered under the Securities Act, or any state securities laws. The Company relied on an exemption
from the registration requirements of the Securities Act under Section 4(a)(2) thereof. The Investor represented that it was acquiring
the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Registration
Rights Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, in connection with the Securities Purchase Agreement, the Company and the Investors entered into a Registration Rights
Agreement (the &#8220;Rights Agreement&#8221;), pursuant to which the Company agreed to use its best efforts to prepare and, as soon
as practicable&#8212;but in no event later than December 31, 2024&#8212;file a registration statement or registration statements (as
necessary) with the United States Securities and Exchange Commission covering the resale of all Common Shares underlying the Series A
Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registration Rights Agreement includes customary representations, warranties, agreements, and indemnification provisions, outlining the
rights and obligations of the parties involved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding summary does not purport to be complete and is qualified in its entirety by reference to Rights Agreement for the Private Placement,
a copy of which is attached hereto as Exhibit 3.3 and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exchange
Agreement with Chen</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Company entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with Yi Hua Chen (&#8220;<b>Chen</b>&#8221;)
pursuant to which we issued 1,154 shares of our newly-designated Series A-2 Convertible Preferred Stock, par value $0.001 per share (the
&#8220;Series A-2 Preferred Stock&#8221;). The Series A-2 Preferred Stock was issued in exchange for the Chen&#8217; $1,100,000 principal
amount convertible notes issued on April 12, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A-2 Preferred Stock and the Common Stock issuable upon conversion of the Series A-2 Preferred Stock (the &#8220;Securities&#8221;)
issued pursuant to the Exchange Agreement are issued in reliance on an exemption from registration under Section 4(a)(2) of the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Rule 506(b) of Regulation D promulgated thereunder. Neither this Current
Report on Form 8-K, nor any Exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the securities described
herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding summary does not purport to be complete and is qualified in its entirety by reference to Exchange Agreement, a copy of which
is attached hereto as Exhibit 3.4 and which are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02. Unregistered Sales of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information provided in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference in this Item 3.02.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.03.</b>&#160;<b>Material Modification to Rights of Security Holders</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information provided in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference in this Item 3.03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Events. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the transactions described above, the Company has equity above $2.5 million as of the date of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statement and Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)
Exhibits.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-1.htm">Securities Purchase Agreement dated November 18, 2024, between Qualigen Therapeutics, Inc. and Certain Investors thereto.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-2.htm">Certificate of Designation of Series A-2 Preferred Stock filed with the Secretary of State of Nevada on November 18, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-3.htm">Registration Right Agreement dated November 18, 2024, between Qualigen Therapeutics, Inc. and Certain Investors thereto.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-4.htm">Exchange Agreement dated November 18, 2024, between Qualigen Therapeutics, Inc. and Yi Hua Chen.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUALIGEN
    THERAPEUTICS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kevin Richardson II</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Richardson II, Interim Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUq3esjHpCKyCJHodcsplnRHZjezT+ovW5VoGBiGe8+9QozEhta6RIbzMkshx6oulUPI8IaM5orekWx3Mfib4V1bx8q4/v2BCXkGPTMfy9nFC7210RaLGKJoIsOJnEG4iKdzOO5F0OkJmZsu0DitSlCmgCNTzRqd4veQkKuWDFXvvuqEbDUZHzcOB/kDMowkHKhRL+KHhTRNRDDqJxAbpmftXavWoelIWJVY+To70P8Nvgi2SpA= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<TEXT>

<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of November 18, 2024 between Qualigen Therapeutics, Inc., a Delaware corporation (the
&ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns,
a &ldquo;<U>Purchaser</U>&rdquo; and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), and Rule 506 of Regulation D promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each
Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this
Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, contemporaneously with
the execution and delivery of this Agreement, each Purchaser and the Company are executing and delivering a registration rights agreement
(the &ldquo;Registration Rights Agreement&rdquo;), substantially in the form attached hereto as Exhibit B (the &ldquo;Registration Rights
Agreement&rdquo;), pursuant to which, among other things, the Company will agree to provide certain registration rights with respect to
the Shares, as defined below, under the Securities Act and the rules and regulations promulgated thereunder and applicable state securities
laws.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B><U>AGREEMENT</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1 <U>Definitions</U>. In addition
to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have the meanings given
to such terms in the Certificate of Designation (as defined herein), and (b) the following terms have the meanings set forth in this Section
1.1:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.7.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Agreement</U>&rdquo;
shall have the meaning ascribed to such term in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">&ldquo;<U>BHCA</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(qq)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Certificate
of Designation</U>&rdquo; means the Certificate of Designation to be filed prior to the Closing by the Company with the Secretary of State
of Delaware, in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Date</U>&rdquo;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and
all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s obligations
to deliver the Securities, in each case, have been satisfied or waived.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock
Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any
time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Counsel</U>&rdquo;
means Sichenzia Ross Ference Carmel LLP, with offices located at 1185 Avenue of the Americas, 31st floor, New York, NY 10036.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning ascribed to such term in the Certificate of Designation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Shares</U>&rdquo; shall have the meaning ascribed to such term in the Certificate of Designation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effective
Date</U>&rdquo; shall have the meaning ascribed to such term in the Certificate of Designation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt Issuance</U>&rdquo;
means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or
option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members
of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise
or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock (or into Common Stock of Parent) issued and outstanding on the date of this Agreement, provided that such
securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend
the term of such securities (it being expressly understood that decreases in the exercise price of warrants (which were outstanding on
the date of this Agreement) pursuant to the operation of ratchet or other antidilution provisions thereof which provisions have not been
amended after the date of this Agreement do not constitute an &ldquo;amendment since the date of this Agreement&rdquo;), and (c) securities
issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, and provided
that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an
operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Federal Reserve</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(qq)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(bb).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(o).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend Removal
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Adverse
Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Permits</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Maximum Rate</U>&rdquo;
shall have the meaning ascribed to such term in Section 5.17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><U>&ldquo;Money Laundering
Laws</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(rr)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>OFAC</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(oo)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Parent</U>&rdquo;
means Ritter Pharmaceuticals, Inc.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Participation
Maximum</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(a).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Notice</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.12(b).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pro Rata Portion</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.12(e).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.10.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required Approvals</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required Minimum</U>&rdquo;
means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable in the future pursuant
to the Transaction Documents, including any Underlying Shares issuable upon conversion in full of all shares of Series A-2 Preferred Stock,
ignoring any conversion limits set forth therein, and assuming that any previously unconverted shares of Series A-2 Preferred Stock are
held until the third anniversary of the Closing Date.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Rights Agreement</U>&rdquo; shall have the meaning ascribed to such term in the Recitals.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Series A-2 Preferred Stock and the Underlying Shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series A-2
Preferred Stock</U>&rdquo; means the up to 10,000 shares of the Company&rsquo;s Series A-2 Preferred Stock issued hereunder having the
rights, preferences and privileges set forth in the Certificate of Designation, in the form of <U>Exhibit A</U> hereto.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stated Value</U>&rdquo;
means $1,000 per share of Series A-2 Preferred Stock.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; shall mean, as to each Purchaser, the aggregate amount to be paid for the Series A-2 Preferred Stock purchased hereunder
as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U> and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question (or,
if the Common Stock is not listed or quoted for trading on any of the following markets or exchanges on the date in question but the common
stock of Parent is listed or quoted for trading on any of the following markets or exchanges on the date in question, then any of the
following markets or exchanges on which the common stock of Parent is listed or quoted for trading on the date in question): the NYSE
American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any
successors to any of the foregoing).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Certificate of Designation, the Registration Rights Agreement, all exhibits and schedules
thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means the current transfer agent of the Company, and any successor transfer agent of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Underlying
Shares</U>&rdquo; means the shares of Common Stock issued and issuable upon conversion of the Series A-2 Preferred Stock in accordance
with the terms of the Certificate of Designation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable Rate
Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.17(b).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ARTICLE II.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PURCHASE AND SALE</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1 <U>Closing</U>. On the Closing
Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this
Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an
aggregate of $4,500,000 of shares of Series A-2 Preferred Stock with an aggregate Stated Value for each Purchaser equal to such Purchaser&rsquo;s
Subscription Amount as set forth on the signature page hereto executed by such Purchaser, as determined by pursuant to Section 2.2(a).
The aggregate number of shares of Series A-2 Preferred Stock sold hereunder shall be up to 4,500. Each Purchaser shall deliver to the
Company via wire transfer immediately available funds equal to such Purchaser&rsquo;s Subscription Amount and the Company shall deliver
to each Purchaser its respective shares of Series A-2 Preferred Stock as determined pursuant to Section 2.2(a), and the Company and each
Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions
set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Sichenzia Ross Ference Carmel LLP or such other location
as the parties shall mutually agree.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.2 <U>Deliveries</U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) On or prior to the
Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i) this Agreement and
the Registration Rights Agreement duly executed by the Company;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii) a legal opinion of
Company Counsel;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii) a book entry statement
evidencing a number of shares of Series A-2 Preferred Stock equal to such Purchaser&rsquo;s Subscription Amount divided by the Stated
Value, registered in the name of such Purchaser;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv) evidence of the filing
and acceptance of the Certificate of Designation from the Secretary of State of Delaware; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(v) the Company shall
have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief Executive Officer
or Chief Financial Officer.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) On or prior to the
Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i) this Agreement and
Registration Rights Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii) such Purchaser&rsquo;s
Subscription Amount by wire transfer to the account specified in writing by the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3 <U>Closing Conditions</U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The obligations
of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i) the accuracy in all
material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in
which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii) all obligations,
covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii) the delivery by
each Purchaser of the items set forth in Section 2.2(b) of this Agreement and the Registration Rights Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The respective obligations
of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i) the accuracy in all
material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects)
when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date
therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii) all obligations,
covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii) the delivery by
the Company of the items set forth in Section 2.2(a) of this Agreement and the Registration Rights Agreement;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv) there shall have
been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(v) from the date hereof
to the Closing Date, trading in the common stock of Parent shall not have been suspended by the Commission or the Company&rsquo;s principal
Trading Market and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have
been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service,
or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE III.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1 <U>Representations and Warranties
of the Company</U>. Except as set forth in the Disclosure Schedules or as set forth in the SEC Reports, which Disclosure Schedules shall
be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the
corresponding section of the Disclosure Schedules (or in any other section of the Disclosure Schedules if its applicability to the corresponding
section of the Disclosure Schedules is apparent), the Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Subsidiaries</U>.
The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;); <I>provided</I>
that a change in the market price or trading volume of the Common Shares alone shall not be deemed, in and itself, to constitute a Material
Adverse Effect. No Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit
or curtail such power and authority or qualification.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party have been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its respective terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>No Conflicts</U>.
The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the
issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not
(i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse
of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company
or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or
Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset
of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not, individually
or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Filings, Consents
and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any
filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with
the execution, delivery and performance by the Company of the Transaction Documents, other than (i) the filing with the Commission pursuant
to the Registration Rights Agreement, (ii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale
of the Securities and the listing of the Shares for trading thereon in the time and manner required thereby, (iii) the filing of Form
D with the Commission, and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Issuance of the
Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents,
will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in the Transaction Documents. The Underlying Shares, when and if issued in accordance with the terms of the Transaction
Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in the Transaction Documents. The Company has reserved from its duly authorized capital stock a number of shares
of Common Stock for issuance of the Underlying Shares at least equal to the Required Minimum on the date hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth in Parent&rsquo;s Form S-1 registration statement filed with the
Commission on October 24, 2024, as thereafter amended. The Company has not issued any capital stock since October 24, 2024, other than
pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of October 24, 2024. No Person has any right of
first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction
Documents or, if such rights exist, such Person has waived any right of first refusal, preemptive right, right of participation, or any
similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale
of the Securities or as disclosed in the Company&rsquo;s Form S-1 registration statement filed with the Commission on October 24, 2024,
as thereafter amended, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person
any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock
Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary
to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or
instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such
security or instrument upon an issuance of securities by the Company or any Subsidiary, except for preferred stock weighted-average antidilution
provisions which have been waived in connection with the transactions contemplated by this Agreement. There are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable,
have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder,
the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(h) RESERVED.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Material Changes;
Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements provided to the Purchasers,
except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has had or that could reasonably
be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other
than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP, (iii) the Company has not altered its method
of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or
purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any
equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. Except for the issuance
of the Securities contemplated by this Agreement or as set forth in the Company&rsquo;s Form S-1 registration statement filed with the
Commission on October 24, 2024, as thereafter amended, no event, liability, fact, circumstance, occurrence or development has occurred
or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses,
prospects, properties, operations, assets or financial condition, that would be required to be disclosed by the Company under applicable
securities laws at the time this representation is made or deemed made that has not been disclosed to the Purchasers.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the
Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been in the past five years,
and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or
any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(k) <U>Labor Relations</U>.
No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could
reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees is a member
of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company nor any of
its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(m) <U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits,
plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received
all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and
(iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii),
the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(n) <U>Regulatory Permits</U>.
The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local
or foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such permits could
not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor
any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(o) <U>Title to Assets</U>.
The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable
title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and
clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the
use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state
or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent
nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under
valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement.
Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included in the SEC Reports,
a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of
any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company,
all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and
value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(q) <U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited
to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that it will not be able
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(r) <U>Transactions
with Affiliates and Employees</U>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company,
none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending
of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
member or partner, in each case in excess of One Hundred Twenty Thousand Dollars ($120,000) other than for (i) payment of salary or consulting
fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including
stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(s) <U>Internal Accounting
Controls</U>. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(t) <U>Certain Fees</U>.
No brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other Person other than Univest Securities LLC with respect to the
transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect
to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with
the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(u) <U>Private Placement</U>.
Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no registration under the Securities
Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v) <U>Investment Company.</U>
The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate
of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct
its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the Investment Company
Act of 1940, as amended.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(w) RESERVED.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(x) RESERVED.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(y) <U>Application of
Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance of
the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(z) <U>Disclosure</U>.
To the knowledge of the Company, all of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company
and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this
Agreement, is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as
a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The
Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(aa) <U>No Integrated
Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither the Company,
nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with
prior offerings by the Company for purposes of the Securities Act which would require the registration of any such securities under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(bb) <U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder (i) the fair saleable value of the Company&rsquo;s assets exceeds the amount
that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known contingent
liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its business as
now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the
business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current
cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into
account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts
are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account
the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances
which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction
within one year from the Closing Date. <U>Schedule 3.1(bb)</U> sets forth as of the date hereof all outstanding secured and unsecured
Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement,
&ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of One Hundred Thousand Dollars
($100,000) (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other
contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of Three Hundred
Thousand Dollars ($300,000) due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary
is in default with respect to any Indebtedness.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(cc) <U>Tax Status</U>.
Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect,
the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and
franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations
and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the
periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the
taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(dd) <U>No General Solicitation</U>.
Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation
or general advertising. The Company has offered the Securities for sale only to the Purchasers and certain other &ldquo;accredited investors&rdquo;
within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ee) <U>Foreign Corrupt
Practices.</U> Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person
acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment
or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which
is in violation of law or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ff) <U>Accountants</U>.
The Company&rsquo;s accounting firm is WithumSmith+Brown, PC. To the knowledge and belief of the Company, such accounting firm (i) is
a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements
to be included in the Company&rsquo;s annual audited financial statements for the fiscal year ending 2024.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(gg) RESERVED.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(hh) <U>No Disagreements
with Accountants and Lawyers.</U> There are no disagreements of any kind presently existing, or reasonably anticipated by the Company
to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is not in
past-due status with respect to any fees owed to its accountants and lawyers which past-due status as to such fees could affect the Company&rsquo;s
ability to perform any of its obligations under any of the Transaction Documents.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) <U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(jj) RESERVED.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(kk) RESERVED.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ll) <U>FDA</U>. As
to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal Food,
Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical Product</U>&rdquo;),
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance
with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket
clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product
listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have
a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit,
arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its
Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the
FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of,
the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical
Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising
or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by
the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters
or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges
any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate,
would have a Material Adverse Effect. <FONT STYLE="letter-spacing: -0.15pt">The properties, business and operations of the Company have
been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company
has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any
product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(mm) RESERVED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(nn) <U>Stock Option
Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance with the
terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock
on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s
stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice
to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public
announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(oo) <U>Office of Foreign
Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(pp) <U>U.S. Real Property
Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section
897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(qq) <U>Bank Holding
Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as
amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(rr) <U>Money Laundering</U>.
The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping
and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes
and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;), and no Action or Proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect
to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ss) <U>No Disqualification
Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of
the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating
in the offering hereunder, any beneficial owner of <FONT STYLE="letter-spacing: -0.15pt">twenty percent (20%)</FONT> or more of the Company&rsquo;s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under
the Securities Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;
and, together, &ldquo;<U>Issuer Covered Persons</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described
in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is
subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e),
and has furnished to the Purchasers a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(tt) <U>Other Covered
Persons</U>. The Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly or
indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(uu) <U>Notice of Disqualification
Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification Event relating to
any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Issuer
Covered Person.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2 <U>Representations and Warranties
of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and
as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such
date):</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Own Account</U>.
Such Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered under the Securities
Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to or
for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities
law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities
law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of
such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting
such Purchaser&rsquo;s right to sell the Securities in compliance with applicable federal and state securities laws). Such Purchaser is
acquiring the Securities hereunder in the ordinary course of its business.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Purchaser Status</U>.
At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it converts
any shares of Series A-2 Preferred Stock, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(4), (a)(5), (a)(6), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional
buyer&rdquo; as defined in Rule 144A(a) under the Securities Act.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Experience of
Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>General Solicitation</U>.
Such Purchaser is not, to such Purchaser&rsquo;s knowledge, purchasing the Securities as a result of any advertisement, article, notice
or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or
radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acknowledges and agrees that the representations
contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations
and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other
document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1 <U>Transfer Restrictions</U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The Securities may
only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities other than pursuant
to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as
contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected
by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to
the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act. As
a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights
and obligations of a Purchaser under this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The Purchasers agree
to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following form:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">[NEITHER] THIS SECURITY [NOR THE SECURITIES
INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [EXERCISE] [CONVERSION] OF THIS
SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL
INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH
SECURITIES.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant
a security interest in some or all of the Securities to a financial institution that is an &ldquo;accredited investor&rdquo; as defined
in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured
Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal
opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall
be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation
as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) Certificates evidencing
the Underlying Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration
statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such Underlying Shares
pursuant to Rule 144, (iii) if such Underlying Shares are eligible for sale under Rule 144, without the requirement for the Company to
be in compliance with the current public information required under Rule 144 as to such Underlying Shares and without volume or manner-of-sale
restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations
and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer
Agent or the Purchaser promptly after the Effective Date if required by the Transfer Agent to effect the removal of the legend hereunder,
or if requested by a Purchaser, respectively. If all or any shares of Series A-2 Preferred Stock are converted at a time when there is
an effective registration statement to cover the resale of the Underlying Shares, or if such Underlying Shares may be sold under Rule
144 and the Company is then in compliance with the current public information required under Rule 144, or if the Underlying Shares may
be sold under Rule 144 without the requirement for the Company to be in compliance with the current public information required under
Rule 144 as to such Underlying Shares and without volume or manner-of-sale restrictions or if such legend is not otherwise required under
applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission)
then such Underlying Shares shall be issued free of all legends. The Company agrees that following the Effective Date or at such time
as such legend is no longer required under this Section 4.1(c), it will, no later than the earlier of (i) two (2) Trading Days and (ii)
the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company
or the Transfer Agent of a certificate representing Underlying Shares, as applicable, issued with a restrictive legend (such date, the
&ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing such shares that
is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer
Agent that enlarge the restrictions on transfer set forth in this Section 4. Certificates for Underlying Shares subject to legend removal
hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with
the Depository Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means
the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the
Common Stock as in effect on the date of delivery of a certificate representing Underlying Shares, as applicable, issued with a restrictive
legend.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) In addition to such
Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated damages and not as
a penalty, for each $1,000 of Underlying Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the
Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing to $20
per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until
such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to a
Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such Purchaser that is free
from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares
of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that
such Purchaser anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such Purchaser&rsquo;s
total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased
(including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<U>Buy-In Price</U>&rdquo;) over the product of
(x) such number of Underlying Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied
by (y) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by
such Purchaser to the Company of the applicable Underlying Shares (as the case may be) and ending on the date of such delivery and payment
under this clause (ii).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e) Each Purchaser,
severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell (if at all and if ever) any
Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements,
or an exemption therefrom, and that if Securities are sold pursuant to a registration statement, they will be sold in compliance with
the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing
Securities as set forth in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2 <U>Acknowledgment of Dilution</U>.
The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution
may be substantial under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents,
including, without limitation, its obligation to issue the Underlying Shares pursuant to the Transaction Documents, are unconditional
and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution
or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership
of the other stockholders of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3 <U>RESERVED.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4 <U>Integration</U>. The Company
shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of
the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration
under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities for purposes
of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other
transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5 <U>Conversion and Exercise
Procedures</U>. Each of the form of Notice of Exercise included in the form of Notice of Conversion included in the Certificate of Designation
set forth the totality of the procedures required of the Purchasers in order to convert the Series A-2 Preferred Stock. Without limiting
the preceding sentences, no ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise or Notice of Conversion form be required in order to convert the Series A-2 Preferred Stock.
No additional legal opinion, other information or instructions shall be required of the Purchasers to convert their Series A-2 Preferred
Stock. The Company shall honor conversions of the Series A-2 Preferred Stock and shall deliver Underlying Shares in accordance with the
terms, conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6 <U>RESERVED</U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.7 <U>Shareholder Rights Plan</U>.
No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &ldquo;<U>Acquiring
Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger
the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement
between the Company and the Purchasers.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.8 <U>RESERVED</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.9 <U>Use of Proceeds</U>. The
Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall not use such proceeds:
(a) for the satisfaction of any portion of the Company&rsquo;s debt (other than IR Agency Payment of $800,000), (b) for the redemption
of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC
regulations.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.10 <U>Indemnification of Purchasers</U>.
Subject to the provisions of this Section 4.10, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders,
members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of
such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims,
contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo;
fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any
of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents
or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder
of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction
Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants
under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined
to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in respect of
which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company
shall have the right to assume the defense thereof (with settlement rights) with counsel of its own choosing reasonably acceptable to
the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume
such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any
material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible
for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party
under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall
not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable
to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party
in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.10 shall be made by periodic payments
of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or
others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.11 <U>Reservation of Securities</U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The Company shall
maintain a reserve of the Required Minimum from its duly authorized shares of Common Stock for issuance pursuant to the Transaction Documents
in such amount as may then be required to fulfill its obligations in full under the Transaction Documents.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) If, on any date,
the number of authorized but unissued (and otherwise unreserved) shares of Common Stock is less than 130% of (i) the Required Minimum
on such date, minus (ii) the number of shares of Common Stock previously issued pursuant to the Transaction Documents, then the Board
of Directors shall use commercially reasonable efforts to amend the Company&rsquo;s certificate or articles of incorporation to increase
the number of authorized but unissued shares of Common Stock to at least the Required Minimum at such time (minus the number of shares
of Common Stock previously issued pursuant to the Transaction Documents), as soon as possible and in any event not later than the 75<SUP>th</SUP>
day after such date, provided that the Company will not be required at any time to authorize a number of shares of Common Stock greater
than the maximum remaining number of shares of Common Stock that could possibly be issued after such time pursuant to the Transaction
Documents.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.12 <U>RESERVED.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">4.13
<U>RESERVED.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.14 <U>Equal Treatment of Purchasers</U>.
No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to
a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties
to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the
Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not
in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities
or otherwise.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.15 <U>Certain Transactions and
Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it, nor any Affiliate
acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales, of any of the
Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the initial press release. Each Purchaser, severally and not jointly
with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by
the Company, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included
in the Disclosure Schedules. The Purchasers shall not be in possession of any material non-public information concerning the Company,
provided to them by the Company and, to the knowledge of the Company, the Purchaser is not an Affiliate of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.16 <U>Blue Sky Filings</U>.
The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify
the Securities for, sale to the Purchasers at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of
the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1 <U>Termination</U>. This Agreement
may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever on the obligations
between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before
the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such termination will affect
the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2 <U>RESERVED.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3 <U>Entire Agreement</U>. The
Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect
to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such
matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4 <U>Notices</U>. Any and all
notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given
and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the
e-mail address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)
the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the e-mail address
as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on
any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and
communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction
Document constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall
simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K or by issuing a press release containing
such material non-public information.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5 <U>Amendments; Waivers</U>.
No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of
an amendment, by the Company and Purchasers which purchased at least 67% in interest of the Series A-2 Preferred Stock based on the initial
Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought,
provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers),
the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with
respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver
of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any
party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6 <U>Headings</U>. The headings
herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions
hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7 <U>Successors and Assigns</U>.
This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may
not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger).
Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities,
provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction
Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.8 <U>No Third-Party Beneficiaries</U>.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.10.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.9 <U>Governing Law</U>. All
questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section
4.10, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10 <U>Survival</U>. The representations
and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.11 <U>Execution</U>. This Agreement
may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties
need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo; format data
file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.12 <U>Severability</U>. If any
term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or
unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect
and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find
and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant
or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms,
provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.13 <U>Rescission and Withdrawal
Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction
Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not
timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion
from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to
its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case of a rescission of a conversion of the Series A-2 Preferred
Stock, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded conversion concurrently
with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.14 <U>Replacement of Securities</U>.
If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to
be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor,
a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.
The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.15 <U>Remedies</U>. In addition
to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and
the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not
be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.16 <U>Payment Set Aside</U>.
To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces
or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are
subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded,
repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any
bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation
or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.17 <U>Usury</U>. To the extent
it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever claim, and will resist any and
all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at any time hereafter in force, in
connection with any Action or Proceeding that may be brought by any Purchaser in order to enforce any right or remedy under any Transaction
Document. Notwithstanding any provision to the contrary contained in any Transaction Document, it is expressly agreed and provided that
the total liability of the Company under the Transaction Documents for payments in the nature of interest shall not exceed the maximum
lawful rate authorized under applicable law (the &ldquo;<U>Maximum Rate</U>&rdquo;), and, without limiting the foregoing, in no event
shall any rate of interest or default interest, or both of them, when aggregated with any other sums in the nature of interest that the
Company may be obligated to pay under the Transaction Documents exceed such Maximum Rate. It is agreed that if the maximum contract rate
of interest allowed by law and applicable to the Transaction Documents is increased or decreased by statute or any official governmental
action subsequent to the date hereof, the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to
the Transaction Documents from the effective date thereof forward, unless such application is precluded by applicable law. If under any
circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to any Purchaser with respect to indebtedness
evidenced by the Transaction Documents, such excess shall be applied by such Purchaser to the unpaid principal balance of any such indebtedness
or be refunded to the Company, the manner of handling such excess to be at such Purchaser&rsquo;s election.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.18 <U>Independent Nature of
Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and not joint
with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of
the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The
Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not
because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained
in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.19 <U>Liquidated Damages</U>.
The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing
obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding
the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall
have been canceled.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.20 <U>Saturdays, Sundays, Holidays,
etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not
be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.21 <U>Construction</U>. The
parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.22 <B><U>WAIVER OF JURY TRIAL</U>.
IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY,
TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL
BY JURY. </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>QUALIGEN THERAPEUTICS, INC.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-size: 10pt">/s/ Kevin Richardson II</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt"><U>Email</U>: </FONT></TD>
    <TD STYLE="width: 44%"><FONT STYLE="font-size: 10pt">kevin@pridescapital.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Kevin Richardson II</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Interim Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With a copy to (which shall not constitute notice)
    to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sichenzia Ross Ference Carmel LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1185 Avenue of the Americas, 31st floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New York, NY 10036</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attn: Ross Carmel, Esq.</P></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Email</U>:</P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">rcarmel@srfc.law</P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[PURCHASER SIGNATURE PAGES TO QUALIGEN SECURITIES PURCHASE
AGREEMENT]</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Purchaser:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Authorized Signatory:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title of Authorized Signatory:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Email Address of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Address for Notice to Purchaser:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Address for Delivery of Securities to Purchaser (if
not same as address for notice):</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subscription Amount: $</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of Series A-2 Preferred Stock:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Certificate of Designation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Registration Rights Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>ex3-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>QUALIGEN
THERAPEUTICS, INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF DESIGNATION OF PREFERENCES,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RIGHTS
AND LIMITATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
A-2 PREFERRED STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">PURSUANT
TO SECTION 151 OF THE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Delaware
GENERAL CORPORATION LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Campbell Becher and Kevin Richardson II, do hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
They are the President and Secretary, respectively, of Qualigen Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Corporation is authorized to issue 15,000,000 shares of Preferred Stock, and no Preferred Stock is currently outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
The following resolutions were duly adopted by the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the certificate of incorporation of the Corporation provides for a class of its authorized stock known as Preferred Stock, consisting
of 15,000,000 shares, $0.001 par value per share, issuable from time to time in one or more series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Board of Directors is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of
redemption and liquidation preferences of any wholly unissued series of Preferred Stock and the number of shares constituting any series
and the designation thereof, of any of them; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and
other matters relating to a series of the Preferred Stock, which shall consist of 10,000 shares of the Preferred Stock which the Corporation
has the authority to issue, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of Preferred Stock for cash or
exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters
relating to such series of Preferred Stock as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TERMS
OF SERIES A-2 PREFERRED STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. For the purposes hereof, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Alternate
Consideration</U>&rdquo; shall have the meaning set forth in Section 7(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bankruptcy
Event</U>&rdquo; means any of the following events: (a) the Corporation or any Significant Subsidiary (as such term is defined in Rule
1-02(w) of Regulation S-X) thereof commences a case or other proceeding under any bankruptcy, reorganization, arrangement, adjustment
of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction relating to the Corporation or
any Significant Subsidiary thereof, (b) there is commenced against the Corporation or any Significant Subsidiary thereof any such case
or proceeding that is not dismissed within 60 days after commencement, (c) the Corporation or any Significant Subsidiary thereof is adjudicated
insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Corporation or
any Significant Subsidiary thereof suffers any appointment of any custodian or the like for it or any substantial part of its property
that is not discharged or stayed within 60 calendar days after such appointment, (e) the Corporation or any Significant Subsidiary thereof
makes a general assignment for the benefit of creditors, (f) the Corporation or any Significant Subsidiary thereof calls a meeting of
its creditors with a view to arranging a composition, adjustment or restructuring of its debts, or (g) the Corporation or any Significant
Subsidiary thereof, by any act or failure to act, expressly indicates its consent to, approval of or acquiescence in any of the foregoing
or takes any corporate or other action for the purpose of effecting any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Base
Conversion Price</U>&rdquo; shall have the meaning set forth in Section 7(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall have the meaning set forth in Section 6(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Buy-In</U>&rdquo;
shall have the meaning set forth in Section 6(c)(iv).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Change
of Control Transaction</U>&rdquo; means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an
individual or legal entity or &ldquo;group&rdquo; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective
control (whether through legal or beneficial ownership of capital stock of the Corporation, by contract or otherwise) of in excess of
39% of the voting securities of the Corporation (other than by means of conversion or exercise of Series A-2 Preferred Stock and the
Securities issued together with the Series A-2 Preferred Stock), (b) the Corporation merges into or consolidates with any other Person,
or any Person merges into or consolidates with the Corporation and, after giving effect to such transaction, the stockholders of the
Corporation immediately prior to such transaction own less than 61% of the aggregate voting power of the Corporation or the successor
entity of such transaction (c) the Corporation sells or transfers all or substantially all of its (and all of its Subsidiaries, taken
as a whole) assets to another Person and the stockholders of the Corporation immediately prior to such transaction own less than 61%
of the aggregate voting power of the acquiring entity immediately after the transaction, (d) a replacement at one time or within a one
year period of more than one-half of the members of the Board of Directors which is not approved by a majority of those individuals who
are members of the Board of Directors on the Original Issue Date (or by those individuals who are serving as members of the Board of
Directors on any date whose nomination to the Board of Directors was approved by a majority of the members of the Board of Directors
who are members on the Original Issue Date), or (e) the execution by the Corporation of an agreement to which the Corporation is a party
or by which it is bound, providing for any of the events set forth in clauses (a) through (d) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the Corporation&rsquo;s common stock, par value $0.001 per share, and stock of any other class of securities into
which such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Amount</U>&rdquo; means the sum of the Stated Value at issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Date</U>&rdquo; shall have the meaning set forth in Section 6(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 6(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Shares</U>&rdquo; means, collectively, the shares of Common Stock issued and issuable upon conversion of the shares of Series A-2 Preferred
Stock in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Dilutive
Issuance</U>&rdquo; shall have the meaning set forth in Section 7(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Dilutive
Issuance Notice</U>&rdquo; shall have the meaning set forth in Section 7(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Corporation
pursuant to any stock or option plan duly adopted by a majority of the non-employee members of the Board of Directors of the Corporation
or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities issued pursuant to,
or upon the exercise or exchange of or conversion of any securities issued or assumed pursuant to, and/or other securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of the Purchase Agreement, provided
that such securities have not been amended since the date of the Purchase Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of any such securities or to extend the term of such securities (it being expressly
understood that decreases in the exercise price of warrants (which were outstanding on the date of the Purchase Agreement) pursuant to
the operation of ratchet or other antidilution provisions thereof which provisions have not been amended after the date of the Purchase
Agreement do not constitute an &ldquo;amendment since the date of the Purchase Agreement&rdquo;), (c) securities issued pursuant to acquisitions
or strategic transactions approved by a majority of the disinterested directors of the Corporation, and provided that any such issuance
shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or
an owner of an asset in a business synergistic with the business of the Corporation and shall provide to the Corporation additional benefits
in addition to the investment of funds, but shall not include a transaction in which the Corporation is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Fundamental
Transaction</U>&rdquo; shall have the meaning set forth in Section 7(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Holder</U>&rdquo;
shall have the meaning given such term in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Junior
Securities</U>&rdquo; means the Common Stock and all other Common Stock Equivalents of the Corporation other than those securities which
are explicitly senior or <U>pari passu</U> to the Series A-2 Preferred Stock in dividend rights or liquidation preference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liquidation</U>&rdquo;
shall have the meaning set forth in Section 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>New
York Courts</U>&rdquo; shall have the meaning set forth in Section 11(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Notice
of Conversion</U>&rdquo; shall have the meaning set forth in Section 6(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Original
Issue Date</U>&rdquo; means the date of the first issuance of any shares of the Series A-2 Preferred Stock regardless of the number of
transfers of any particular shares of Series A-2 Preferred Stock and regardless of the number of certificates which may be issued to
evidence such Series A-2 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Securities Purchase Agreement, dated on November 18, 2024, among Qualigen Therapeutics, Inc. and certain
person(s) who would become the original Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to
time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Series A-2 Preferred Stock and the Conversion Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
A-2 Preferred Stock</U>&rdquo; shall have the meaning set forth in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Share
Delivery Date</U>&rdquo; shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stated
Value</U>&rdquo; shall have the meaning set forth in Section 2, as the same may be increased pursuant to Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any entity which is currently or hereafter a direct or indirect subsidiary of the Corporation, for so long as such subsidiary relationship
persists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Successor
Entity</U>&rdquo; shall have the meaning set forth in Section 7(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Certificate of Designation, the Purchase Agreement (to the extent binding upon or benefiting the Corporation),
all exhibits and schedules thereto (to the extent binding upon or benefiting the Corporation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means the current transfer agent of the Corporation, and any successor transfer agent of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; means a transaction in which the Corporation (i) issues or sells any debt or equity securities that are convertible
into, exchangeable or exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion
price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for
the shares of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise
or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon
the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the
Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit,
whereby the Company may issue securities at a future determined price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Corporation,
the fees and expenses of which shall be paid by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Designation, Amount and Par Value</U>. This series of Preferred Stock of the Corporation shall be designated as its Series
A-2 Preferred Stock (the &ldquo;<U>Series A-2 Preferred Stock</U>&rdquo;) and the number of shares so designated shall be 7,000 (which
shall not be subject to increase without the written consent of the holders of a majority of the then outstanding shares of the Series
A-2 Preferred Stock (each, a &ldquo;<U>Holder</U>&rdquo; and collectively, the &ldquo;<U>Holders</U>&rdquo;)). Each share of Series A-2
Preferred Stock shall have a par value of $0.001 per share and a stated value equal to $1,000, subject to increase set forth in Section
3 below (the &ldquo;<U>Stated Value</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Dividends</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>As If Common Stock</U>. If the Corporation, at any time while any shares of Series A-2 Preferred Stock are outstanding, pays a dividend
or distribution (other than one payable in shares of Common Stock or in Common Stock Equivalents) on shares of Common Stock, Holders
as of the record date for such dividend or distribution on Common Stock shall be entitled to receive at the same time as such payment
on Common Stock, and the Corporation shall pay, a dividend or distribution on each share of Series A-2 Preferred Stock equal to the per-share
amount of the dividend or distribution on Common Stock multiplied by the number of shares of Common Stock into which such share of Series
A-2 Preferred Stock was (on such record date) convertible (without regard to any limitations on conversion, including without limitation
the Beneficial Ownership Limitation). Such dividend or distribution on Series A-2 Preferred Stock shall be paid in the same form as the
dividend or distribution on Common Stock. The Series A-2 Preferred Stock shall not otherwise have any rights to dividends. The fair market
value of any dividend or distribution to which a share of Series A-2 Preferred Stock has become entitled pursuant to this Section but
which has not yet been paid shall, until such dividend or distribution has been paid on such share of Series A-2 Preferred Stock, be
added to the Stated Value of such share of Series A-2 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Other Securities</U>. So long as any Series A-2 Preferred Stock shall remain outstanding, neither the Corporation nor any Subsidiary
thereof shall redeem, purchase or otherwise acquire directly or indirectly any Junior Securities nor shall any monies be set aside for
or applied to the purchase or redemption (through a sinking fund or otherwise) of any Junior Securities or shares <U>pari passu</U> with
the Series A-2 Preferred Stock, in each case except as expressly permitted by Section 8(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Voting Rights</U>. The Series A-2 Preferred Stock shall have the right to vote, together with the Common Stock as if all part
of a single class and single series, as to all matters on which the Common Stock is entitled to vote, and each then-outstanding share
of Series A-2 Preferred Stock shall as to each respective matter to be so voted upon be entitled to a number of votes equal to the number
of shares of Common Stock into which such share of Series A-2 Preferred Stock would be, as of the record date for determination of stockholders
entitled to vote as to such matter, convertible if the conversion price was equal to the &ldquo;Minimum Price&rdquo; (as of the Original
Issue Date) as defined in Nasdaq Listing Rule 5635(d) (without giving effect to any post-Original Issue Date amendments of such Rule),
taking into account for such purposes the Beneficial Ownership Limitation as then in effect. Provided, that such deemed &ldquo;conversion
price&rdquo; shall be adjusted to reflect proportionally any changes in the actual Conversion Price pursuant to Section 7(a) below; but
in the event of a Dilutive Issuance resulting in a &ldquo;ratchet&rdquo; change in the actual Conversion Price pursuant to Section 7(b)
below, there shall be no voting rights adjustment of such &ldquo;deemed&rdquo; conversion price as a result of such Dilutive Issuance
or as a result of such &ldquo;ratchet&rdquo; change in the actual Conversion Price pursuant to Section 7(b) below. Holders shall be entitled
to notice of all meetings of Corporation stockholders on the same basis as holders of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Liquidation</U>. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &ldquo;<U>Liquidation</U>&rdquo;),
the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated
Value and any fees or liquidated damages then due and owing thereon under this Certificate of Designation, for each share of Series A-2
Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation
shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be ratably distributed
among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were
paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
6</U>. <U>Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Conversions at Option of Holder</U>. Each share of Series A-2 Preferred Stock shall be convertible, at any time and from time to time
from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the
limitations set forth in Section 6(d)) determined by dividing the Stated Value of such share of Series A-2 Preferred Stock by the Conversion
Price. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <U>Annex A
</U>(a &ldquo;<U>Notice of Conversion</U>&rdquo;). Each Notice of Conversion shall specify the number of shares of Series A-2 Preferred
Stock to be converted, the number of shares of Series A-2 Preferred Stock owned prior to the conversion at issue, the number of shares
of Series A-2 Preferred Stock owned subsequent to the conversion at issue and the date on which such conversion is to be effected, which
date may not be prior to the date the applicable Holder delivers by email such Notice of Conversion to the Corporation (such date, the
&ldquo;<U>Conversion Date</U>&rdquo;). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the
date that such Notice of Conversion to the Corporation is deemed delivered hereunder. No ink-original Notice of Conversion shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. The calculations
and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. To effect conversions
of shares of Series A-2 Preferred Stock, a Holder shall not be required to surrender the certificate(s) representing the shares of Series
A-2 Preferred Stock to the Corporation unless all of the shares of Series A-2 Preferred Stock represented thereby are so converted, in
which case such Holder shall deliver the certificate representing such shares of Series A-2 Preferred Stock promptly following the Conversion
Date at issue. Shares of Series A-2 Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof shall
be canceled and shall not be reissued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Conversion Price</U>. The conversion price for the Series A-2 Preferred Stock shall equal $<B>3.64 </B>subject to adjustment herein
(the &ldquo;<U>Conversion Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Mechanics of Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &ldquo;<U>Share Delivery Date</U>&rdquo;),
the Corporation shall deliver, or cause to be delivered, to the converting Holder the number of Conversion Shares being acquired upon
the conversion of the Series A-2 Preferred Stock, which, on or after the six month anniversary of the Original Issue Date, shall be free
of restrictive legends and trading restrictions (other than those which may then be required by the Purchase Agreement or under applicable
law). On or after the six month anniversary of the Original Issue Date, the Corporation shall deliver the Conversion Shares required
to be delivered by the Corporation under this Section 6 electronically through the Depository Trust Company or another established clearing
corporation performing similar functions. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement
period, expressed in a number of Trading Days, on the Corporation&rsquo;s primary Trading Market with respect to the Common Stock as
in effect on the date of delivery of the Notice of Conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Failure to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to
or as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation
at any time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event the Corporation shall promptly
return to the Holder any original Series A-2 Preferred Stock certificate delivered to the Corporation and the Holder shall promptly return
to the Corporation the Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Obligation Absolute; Partial Liquidated Damages</U>. The Corporation&rsquo;s obligation to issue and deliver the Conversion Shares
upon conversion of Series A-2 Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any
action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment
against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach
or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law
by such Holder or any other person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation
to such Holder in connection with the issuance of such Conversion Shares; <U>provided</U>, <U>however</U>, that such delivery shall not
operate as a waiver by the Corporation of any such action that the Corporation may have against such Holder. In the event a Holder shall
elect to convert any or all of the Stated Value of its Series A-2 Preferred Stock, the Corporation may not refuse conversion based on
any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, agreement or
for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part
of the Series A-2 Preferred Stock of such Holder shall have been sought and obtained, and the Corporation posts a surety bond for the
benefit of such Holder in the amount of 150% of the Stated Value of Series A-2 Preferred Stock which is subject to the injunction, which
bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall
be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall issue Conversion
Shares and, if applicable, cash, upon a properly noticed conversion. If the Corporation fails to deliver to a Holder such Conversion
Shares pursuant to Section 6(c)(i) by the Share Delivery Date applicable to such conversion, the Corporation shall pay to such Holder,
in cash, as liquidated damages and not as a penalty, for each $5,000 of Stated Value of Series A-2 Preferred Stock being converted, $50
per Trading Day (increasing to $100 per Trading Day on the third Trading Day and increasing to $200 per Trading Day on the sixth Trading
Day after such damages begin to accrue) for each Trading Day after the Share Delivery Date until such Conversion Shares are delivered
or Holder rescinds such conversion. Nothing herein shall limit a Holder&rsquo;s right to pursue actual damages or declare a Triggering
Event pursuant to Section 10 hereof for the Corporation&rsquo;s failure to deliver Conversion Shares within the period specified herein
and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief. The exercise of any such rights shall not prohibit a Holder from seeking to
enforce damages pursuant to any other Section hereof or under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available
to the Holder, if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery
Date pursuant to Section 6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in
an open market transaction or otherwise), or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating
to such Share Delivery Date (a &ldquo;<U>Buy-In</U>&rdquo;), then the Corporation shall (A) pay in cash to such Holder (in addition to
any other remedies available to or elected by such Holder) the amount, if any, by which (x) such Holder&rsquo;s total purchase price
(including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares
of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which
the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such
Holder, either reissue (if surrendered) the shares of Series A-2 Preferred Stock equal to the number of shares of Series A-2 Preferred
Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the number of shares
of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section 6(c)(i).
For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to
an attempted conversion of shares of Series A-2 Preferred Stock with respect to which the actual sale price of the Conversion Shares
(including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately
preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice
indicating the amounts payable to such Holder in respect of the Buy-In and, upon request of the Corporation, evidence of the amount of
such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&rsquo;s failure
to timely deliver the Conversion Shares upon conversion of the shares of Series A-2 Preferred Stock as required pursuant to the terms
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>Reservation of Shares Issuable Upon Conversion</U>. The Corporation covenants that it will at all times reserve and keep available
out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A-2 Preferred
Stock as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder
(and the other holders of the Series A-2 Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall
be issuable (taking into account the adjustments and restrictions of Section 7) upon the conversion of the then outstanding shares of
Series A-2 Preferred Stock hereunder. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon
issue, be duly authorized, validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Fractional Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series
A-2 Preferred Stock. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the
Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Conversion Price or round up to the next whole share. Notwithstanding anything to the contrary contained herein, but
consistent with the provisions of this subsection with respect to fractional Conversion Shares, nothing shall prevent any Holder from
converting fractional shares of Series A-2 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Transfer Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of this Series A-2 Preferred Stock shall be made
without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such
Conversion Shares, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer
involved in the issuance and delivery of any such Conversion Shares upon conversion in a name other than that of the Holders of such
shares of Series A-2 Preferred Stock and the Corporation shall not be required to issue or deliver such Conversion Shares unless or until
the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established
to the satisfaction of the Corporation that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for same-day
processing of any Notice of Conversion and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Conversion Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Beneficial Ownership Limitation</U>. The Corporation shall not effect any conversion of the Series A-2 Preferred Stock, and a Holder
shall not have the right to convert any portion of the Series A-2 Preferred Stock, to the extent that, after giving effect to the conversion
set forth on the applicable Notice of Conversion, such Holder (together with such Holder&rsquo;s Affiliates, and any Persons acting as
a group together with such Holder or any of such Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;))
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by such Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon conversion of the Series A-2 Preferred Stock with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted Stated
Value of Series A-2 Preferred Stock beneficially owned by such Holder or any of its Affiliates or Attribution Parties and (ii) exercise
or conversion of the unexercised or unconverted portion of any other securities of the Corporation subject to a limitation on conversion
or exercise analogous to the limitation contained herein (including, without limitation, the Series A-2 Preferred Stock or the Warrants)
beneficially owned by such Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for
purposes of this Section 6(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the
rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 6(d) applies, the determination
of whether the Series A-2 Preferred Stock is convertible (in relation to other securities owned by such Holder together with any Affiliates
and Attribution Parties) and of how many shares of Series A-2 Preferred Stock are convertible shall be in the sole discretion of such
Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&rsquo;s determination of whether the shares of
Series A-2 Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates and Attribution
Parties) and how many shares of the Series A-2 Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation.
To ensure compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers a Notice
of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 6(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as stated in the most recent of the following: (i) the Corporation&rsquo;s most recent periodic or
annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Corporation or (iii) a more
recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the
written or oral request of a Holder, the Corporation shall within one Trading Day confirm orally and in writing to such Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to the conversion or exercise of securities of the Corporation, including the Series A-2 Preferred Stock, by such Holder or its
Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon conversion of Series A-2 Preferred Stock held by the applicable Holder. A Holder,
upon notice to the Corporation, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 6(d) applicable
to its Series A-2 Preferred Stock provided that the Beneficial Ownership Limitation in no event exceeds 4.99% (or 9.99% upon the election
of the Holder) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock upon conversion of this Series A-2 Preferred Stock held by the Holder and the provisions of this Section 6(d) shall continue to
apply. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice
is delivered to the Corporation and shall only apply to such Holder and no other Holder. The provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section 6(d) to correct this paragraph (or any
portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of Series A-2 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
7</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while any shares of Series A-2 Preferred Stock are outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock
or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation
upon conversion of, or payment of a dividend on, this Series A-2 Preferred Stock), (ii) subdivides outstanding shares of Common Stock
into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a
smaller number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock
of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section
7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Equity Sales</U>. If, at any time while any shares of Series A-2 Preferred Stock are outstanding, the Corporation or any
Subsidiary, as applicable sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or
issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling
any Person to acquire shares of Common Stock at an effective price per share that is lower than the then Conversion Price (such lower
price, the &ldquo;<U>Base Conversion Price</U>&rdquo; and such issuances, collectively, a &ldquo;<U>Dilutive Issuance</U>&rdquo;) (if
the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments,
reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which
are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower
than the Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive
Issuance), then simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance the Conversion Price
shall be reduced to equal the higher of (i) the Base Conversion Price or (ii) <B>$1.82</B> (the &ldquo;<U>Floor Price</U>&rdquo; &ndash;
such Floor Price to be subject to adjustment in accordance with, but only in accordance with, Section 7(a)). Notwithstanding the foregoing,
no adjustment will be made under this Section 7(b) in respect of an Exempt Issuance or in respect of any repricing (triggered or effected
after the Original Issue Date) of any derivative securities which were outstanding as of the Original Issue Date. (Standard stock-split-type
adjustments under Section 7(a) are not &ldquo;repricings&rdquo; for this purpose.) If the Corporation enters into a Variable Rate Transaction,
despite the prohibition set forth in the Purchase Agreement, the Corporation shall be deemed to have issued Common Stock or Common Stock
Equivalents at the lowest possible conversion price at which such securities may be converted or exercised. The Corporation shall notify
the Holders in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject
to this Section 7(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and
other pricing terms (such notice, the &ldquo;<U>Dilutive Issuance Notice</U>&rdquo;). For purposes of clarification, whether or not the
Corporation provides a Dilutive Issuance Notice pursuant to this Section 7(b), upon the occurrence of any Dilutive Issuance, the Holders
are entitled to receive a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance,
regardless of whether a Holder accurately refers to the Base Conversion Price in the Notice of Conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete conversion of such Holder&rsquo;s Series A-2 Preferred Stock (without
regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided,
however, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall
be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Pro Rata Distributions</U>. During such time as any shares of Series A-2 Preferred Stock are outstanding, if the Corporation declares
or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by
way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Series A-2 Preferred Stock, then, in each such case, the
Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the
Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Series A-2 Preferred Stock (without
regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of
shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent
that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Fundamental Transaction</U>. If, at any time while any shares of Series A-2 Preferred Stock are outstanding, (i) the Corporation,
directly or indirectly, in one or more related transactions effects any merger or consolidation of the Corporation with or into another
Person, (ii) the Corporation (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license,
assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions,
(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed
pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property
and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or
other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with
another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of
Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent conversion of this Series A-2 Preferred Stock, the Holder shall have the right to receive, for each Conversion
Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without
regard to any limitation in Section 6(d) on the conversion of this Series A-2 Preferred Stock), the number of shares of Common Stock
of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration
(the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of
shares of Common Stock for which this Series A-2 Preferred Stock is convertible immediately prior to such Fundamental Transaction (without
regard to any limitation in Section 6(d) on the conversion of this Series A-2 Preferred Stock). For purposes of any such conversion,
the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount
of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall
apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any conversion of this Series A-2 Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate
the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate
of Designation with the same terms and conditions and issue to the Holders new Series A-2 Preferred Stock consistent with the foregoing
provisions and evidencing the Holders&rsquo; right to convert such Series A-2 Preferred Stock into Alternate Consideration. The Corporation
shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents
in accordance with the provisions of this Section 7(e) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the holder of this Series A-2 Preferred Stock, deliver to the Holder in exchange for this Series A-2 Preferred Stock a security of the
Successor Entity evidenced by a written instrument substantially similar in form and substance to this Series A-2 Preferred Stock which
is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon conversion of this Series A-2 Preferred Stock (without regard to any limitations
on the conversion of this Series A-2 Preferred Stock) prior to such Fundamental Transaction, and with a conversion price which applies
the conversion price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
conversion price being for the purpose of protecting the economic value of this Series A-2 Preferred Stock immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such
Fundamental Transaction, the provisions of this Certificate of Designation referring to the &ldquo;Corporation&rdquo; shall refer instead
to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation
under this Certificate of Designation with the same effect as if such Successor Entity had been named as the Corporation herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice to the Holders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation
shall promptly deliver to each Holder by email a notice setting forth the Conversion Price after such adjustment and setting forth a
brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Conversion by Holder</U>. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)
the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any
shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer
of all or substantially all of the assets of the Corporation (and all of its Subsidiaries, taken as a whole), or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary
or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause
to be filed at each office or agency maintained for the purpose of conversion of this Series A-2 Preferred Stock, and shall cause to
be delivered by email to each Holder at its last email address as it shall appear upon the stock books of the Corporation, at least twenty
(20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record
is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the
date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected
to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
hereunder constitutes, or contains, material, non-public information regarding the Corporation or any of the Subsidiaries, the Corporation
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled
to convert the Conversion Amount of this Series A-2 Preferred Stock (or any part hereof) during the 20-day period commencing on the date
of such notice through the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
8</U>. <U>Negative Covenants</U>. As long as any shares of Series A-2 Preferred Stock are outstanding, unless the holders of at least
67% in Stated Value of the then outstanding shares of Series A-2 Preferred Stock shall have otherwise given prior written consent, the
Corporation shall not, and shall not permit any of the Subsidiaries to, directly or indirectly:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
amend its charter documents, including, without limitation, its certificate of incorporation and bylaws, in any manner that materially
and adversely affects any rights of the Holder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
repay, repurchase or offer to repay, repurchase or otherwise acquire more than a <U>de minimis</U> number of shares of its Common Stock,
Common Stock Equivalents or Junior Securities, other than as to (i) shares issued upon exercise of the Warrants, or the Conversion Shares,
in each case as permitted or required under the Transaction Documents, and (ii) repurchases of Common Stock or Common Stock Equivalents
of departing officers and directors of the Corporation, provided that such repurchases shall not exceed an aggregate of $100,000 for
all officers and directors for so long as the Series A-2 Preferred Stock is outstanding;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
pay cash dividends or distributions on Junior Securities of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
enter into any transaction with any Affiliate of the Corporation which would be required to be disclosed in any public filing with the
Commission, unless such transaction is made on an arm&rsquo;s-length basis and expressly approved by a majority of the disinterested
directors of the Corporation (even if less than a quorum otherwise required for board approval); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
enter into any agreement with respect to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
9</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Conversion, shall be in writing and delivered personally, by e-mail attachment, or sent by a nationally recognized
overnight courier service, addressed to the Corporation, at Qualigen Therapeutics, Inc., 5857 Owens Avenue, Suite 300, Carlsbad, California
92008, Attention: Interim Chief executive Officer, e-mail address kevin@pridescapital.com, or such other e-mail address or address as
the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 9. Any and all notices
or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by e-mail
attachment, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of
such Holder appearing on the books of the Corporation, or if no such e-mail address or address appears on the books of the Corporation,
at the principal place of business of such Holder, as set forth in the Purchase Agreement. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered
via e-mail attachment at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next
Trading Day after the time of transmission, if such notice or communication is delivered via e-mail attachment at the e-mail address
set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the
second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual
receipt by the party to whom such notice is required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Absolute Obligation</U>. Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair
the obligation of the Corporation, which is absolute and unconditional, to pay liquidated damages, accrued dividends and accrued interest,
as applicable, on the shares of Series A-2 Preferred Stock at the time, place, and rate, and in the coin or currency, herein prescribed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Lost or Mutilated Series A-2 Preferred Stock Certificate</U>. If a Holder&rsquo;s Series A-2 Preferred Stock certificate shall be
mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation
of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares
of Series A-2 Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction
of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation
shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the
principles of conflict of laws thereof. All legal proceedings concerning the interpretation, enforcement and defense of the transactions
contemplated by this Certificate of Designation (whether brought against a party hereto or its respective Affiliates, directors, officers,
shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan
(the &ldquo;<U>New York Courts</U>&rdquo;). The Corporation and each Holder hereby irrevocably submits to the exclusive jurisdiction
of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein (including with respect to the enforcement of this Certificate of Designation), and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York
Courts, or such New York Courts are improper or inconvenient venue for such proceeding. The Corporation and each Holder hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by applicable law. The Corporation and each Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and
all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions
contemplated hereby. If the Corporation or any Holder shall commence an action or proceeding to enforce any provisions of this Certificate
of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys&rsquo;
fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Waiver</U>. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate
as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of
Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term
of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder)
of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation on any other
occasion. Any waiver by the Corporation or a Holder must be in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Severability</U>. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate
of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain
applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder
violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the
maximum rate of interest permitted under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Next Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment
shall be made on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Headings</U>. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation
and shall not be deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Status of Converted or Redeemed Series A-2 Preferred Stock</U>. If any shares of Series A-2 Preferred Stock shall be converted, redeemed
or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of Series A-2 Preferred Stock
and shall no longer be designated as Series A-2 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESOLVED,
FURTHER, that the president and the secretary of the Corporation be and they hereby are authorized and directed to prepare and file a
Certificate of Designation of Preferences, Rights and Limitations in accordance with the foregoing resolution and the provisions of Delaware
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have executed this Certificate of Designation of Preferences, Rights and Limitations this 18th day of
November, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Campbell Becher</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Kevin Richardson II</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Campbell
    Becher</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Richardson II</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNEX
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
OF CONVERSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">(To
be Executed by the Registered Holder in order to Convert Shares of Series A-2 Preferred Stock)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby elects to convert the number of shares of Series A-2 Preferred Stock indicated below into shares of common stock,
par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of Qualigen Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;),
according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a Person
other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such
certificates and opinions as may be reasonably required by the Corporation. No fee will be charged to the Holders for any conversion,
except for any such transfer taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
calculations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
to Effect Conversion: _____________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of shares of Series A-2 Preferred Stock owned prior to Conversion: _______________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of shares of Series A-2 Preferred Stock to be Converted: ________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stated
Value of shares of Series A-2 Preferred Stock to be Converted: ____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of shares of Common Stock to be Issued: ___________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
Conversion Price:____________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of shares of Series A-2 Preferred Stock subsequent to Conversion: ________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery: ______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>or</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DWAC
Instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker
no: _________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account
no: ___________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[HOLDER]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>ex3-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">Exhibit
3.3</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION
RIGHTS AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Rights Agreement (this &ldquo;<U>Agreement</U>&rdquo;), dated as of <U>November 18</U>, 2024 is by and among each person
named on the signature page hereto (each, an &ldquo;<U>Investor</U>&rdquo; and collectively, the &ldquo;<U>Investors</U>&rdquo;), and
Qualigen Therapeutics, Inc., a Delaware corporation(the &ldquo;<U>Company</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECITALS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company and the Investors have entered into that certain Securities Purchase Agreement, dated as of the date hereof (the &ldquo;<U>Purchase
Agreement</U>&rdquo;), pursuant to which the Company has agreed, upon the terms and subject to the conditions of the Purchase Agreement,
to issue and sell to the Investors certain shares of Series A-2 Preferred Stock in accordance with the terms of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
pursuant to the terms of, and in consideration for the Investors entering into, the Purchase Agreement, and to induce the Investors to
execute and deliver the Purchase Agreement, the Company has agreed to provide the Investors with certain registration rights with respect
to the Registrable Securities (as defined herein) as set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>AGREEMENT</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the representations, warranties, covenants, and agreements contained herein and in the Purchase Agreement,
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound
hereby, the Company and the Investors hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Definitions</U>. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the
Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Agreement</U>&rdquo;
shall have the meaning assigned to such term in the preamble of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Blue
Sky Filing</U>&rdquo; shall have the meaning assigned to such term in <U>Section 6(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday, or any other day on which commercial banks in New York, New York are authorized
or required by law to remain closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Claims</U>&rdquo;
shall have the meaning assigned to such term in <U>Section 6(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the U.S. Securities and Exchange Commission or any successor entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the Company&rsquo;s common stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company</U>&rdquo;
shall have the meaning assigned to such term in the preamble of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Party</U>&rdquo; shall have the meaning assigned to such term in <U>Section 6(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Current
Public Information Failure</U>&rdquo; shall have the meaning assigned to such term in <U>Section 2(g)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EDGAR</U>&rdquo;
means the Electronic Data Gathering, Analysis, and Retrieval system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; means the date that the applicable Registration Statement has been declared effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities and Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Filing
Deadline</U>&rdquo; shall have the meaning assigned to such term in <U>Section 2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnified
Damages</U>&rdquo; shall have the meaning assigned to such term in <U>Section 6(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Investor</U>&rdquo;
shall have the meaning assigned to such term in the preamble of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Investor
Party</U>&rdquo; and &ldquo;<U>Investor Parties</U>&rdquo; shall have the meaning assigned to such terms in <U>Section 6(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company,
trust, unincorporated organization, business association, firm, joint venture, governmental agency, or authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the prospectus in the form included in a Registration Statement, as supplemented from time to time by any Prospectus Supplement,
including the documents incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means any prospectus supplement to a Prospectus filed with the Commission from time to time pursuant to Rule 424(b)
under the Securities Act, including the documents incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; shall have the meaning assigned to such term in the recitals to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>register</U>,&rdquo;
&ldquo;<U>registered</U>,&rdquo; and &ldquo;<U>registration</U>&rdquo; refer to a registration effected by preparing and filing one or
more Registration Statements in compliance with the Securities Act and pursuant to Rule 415 and the declaration of effectiveness of such
Registration Statement(s) by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registrable
Securities</U>&rdquo; means (i) any shares of Common Stock issued and issuable upon conversion of the Series A-2 Preferred Stock or (ii)
any Common Stock issued or issuable with respect to the securities referred to in the preceding clause (i) by way of a stock dividend
or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization. As to
any particular Registrable Securities, such securities shall cease to be Registrable Securities on the earlier of the (i) one (1) year
anniversary of the Effective Date or (ii) on such date that such Investor may sell all of the Registrable Securities owned by such Investor
pursuant to Rule 144 of the Securities Act without any restrictions as to volume or manner of sale or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement or registration statements of the Company filed under the Securities Act covering
the resale by the Investors of Registrable Securities, as such registration statement or registration statements may be amended and supplemented
from time to time, including all documents filed as part thereof or incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Period</U>&rdquo; shall have the meaning assigned to such term in <U>Section 3(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time,
or any other similar or successor rule or regulation of the Commission that may at any time permit the Investors to sell securities of
the Company to the public without registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
415</U>&rdquo; means Rule 415 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time,
or any other similar or successor rule or regulation of the Commission providing for offering securities on a delayed or continuous basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Series
A-2 Preferred Stock&rdquo; means the up to 10,000 shares of the Company&rsquo;s Series A-2 Preferred Stock issued hereunder having the
rights, preferences and privileges set forth in the Certificate of Designation, in the form of Exhibit A in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Staff</U>&rdquo;
shall have the meaning assigned to such term in <U>Section 2(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Violations</U>&rdquo;
shall have the meaning assigned to such term in <U>Section 6(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Mandatory Registration</U>. At the Company&rsquo;s own expense, the Company shall prepare and, as soon as practicable, but in no event
later than December 31, 2024 (the &ldquo;<U>Filing Deadline</U>&rdquo;), file with the Commission an initial Registration Statement on
Form S-1 covering the resale of all of the Registrable Securities. Such initial Registration Statement, and each other Registration Statement
required to be filed pursuant to the terms of this Agreement, shall contain (except if otherwise directed by the Investors) the &ldquo;<U>Selling
Stockholder</U>&rdquo; and &ldquo;<U>Plan of Distribution</U>&rdquo; sections. The Company shall use its commercially reasonable efforts
to have such initial Registration Statement, and each other Registration Statement required to be filed pursuant to the terms of this
Agreement, declared effective by the Commission as soon as practicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Reserved.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Sufficient Number of Shares Registered</U>. In the event the number of shares available under any Registration Statement is insufficient
to cover all of the Registrable Securities required to be covered by such Registration Statement, the Company shall amend such Registration
Statement (if permissible), or file with the Commission a new Registration Statement on Form S-1 (or, if the Company is eligible to use
a Registration Statement on Form S-3, a new Registration Statement on Form S-3), or both, so as to cover all of the Registrable Securities,
in each case, as soon as practicable, but in any event not later than fifteen (15) Trading Days after the necessity therefor arises (but
taking account of any Staff position with respect to the date on which the Staff will permit such amendment to the Registration Statement
and/or such new Registration Statement (as the case may be) to be filed with the Commission). The Company shall use its commercially
reasonable efforts to cause such amendment to such Registration Statement and/or such new Registration Statement (as the case may be)
to become effective as soon as practicable and following the filing thereof with the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Reserved.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Ineligibility to Use Form S-3</U>. In the event that the Company files a Form S-1 for the registration of the resale of Registrable
Securities hereunder, the Company shall use its commercially reasonable efforts to convert the Registration Statement on Form S-1 (and
any subsequent Registration Statement) to a Registration Statement on Form S-3 as soon as practicable after the Company is eligible to
use Form S-3; <I>provided </I>that the Company shall maintain the effectiveness of all Registration Statements then in effect until such
time as a Registration Statement on Form S-3 covering the resale of all the Registrable Securities has been declared effective by the
Commission and the Prospectus contained therein is available for use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Related Obligations</U>. The Company shall use its commercially reasonable efforts to effect the registration of the Registrable Securities
in accordance with the intended method of disposition thereof, and, pursuant thereto, the Company shall have the following obligations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall use commercially reasonable efforts to keep each Registration Statement effective (and the Prospectus contained therein
available for use) pursuant to Rule 415 for resales by the Investors on a continuous basis at then-prevailing market prices (and not
fixed prices) at all times until the earliest of (i) the date on which the Investors shall have sold all of the Registrable Securities
covered by such Registration Statement or (ii) the date as of which the Investors may sell all of the Registrable Securities required
to be covered by such Registration Statement (disregarding any reduction pursuant to <U>Section 2(e)</U>) without restriction pursuant
to Rule 144 (including, without limitation, volume restrictions) and without the need for current public information required by Rule
144(c)(1) (or Rule 144(i)(2), if applicable) (the &ldquo;<U>Registration Period</U>&rdquo;). Notwithstanding anything to the contrary
contained in this Agreement, the Company shall use its commercially reasonable efforts to ensure that, when filed and at all times while
effective, each Registration Statement (including, without limitation, all amendments and supplements thereto) and the Prospectus (including,
without limitation, all amendments and supplements thereto) used in connection with such Registration Statement shall not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements
therein (in the case of Prospectuses, in light of the circumstances in which they were made) not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company shall use its commercially reasonable efforts to prepare and file with the Commission such amendments (including, without
limitation, post-effective amendments) and supplements to each Registration Statement and the Prospectus used in connection with each
such Registration Statement, which Prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary
to keep each such Registration Statement effective (and the Prospectus contained therein current and available for use) at all times
during the Registration Period for such Registration Statement, and, during such period, comply with the provisions of the Securities
Act with respect to the disposition of all Registrable Securities of the Company covered by such Registration Statement until such time
as all of such Registrable Securities shall have been disposed of in accordance with the intended methods of disposition by the Investors
as set forth in such Registration Statement. Without limiting the generality of the foregoing, the Company covenants and agrees that
at or before 8:30 a.m. (New York City time) on the Trading Day immediately following the Effective Date of any Registration Statement
(or any post-effective amendment thereto), the Company shall file with the Commission in accordance with Rule 424(b) under the Securities
Act the final Prospectus to be used in connection with issuances and/or conversions pursuant to such Registration Statement (or post-effective
amendment thereto). In the case of amendments and supplements to any Registration Statement on Form S-1 or Prospectus related thereto
which are required to be filed pursuant to this Agreement (including, without limitation, pursuant to this <U>Section 3(b)</U>) by reason
of the Company filing a report on Form 8-K, Form 10-Q, or Form 10-K or any analogous report under the Exchange Act, the Company shall
have incorporated such report by reference into such Registration Statement and Prospectus, if applicable, or shall file such amendments
or supplements to the Registration Statement or Prospectus with the Commission on the same day on which the Exchange Act report is filed
which created the requirement for the Company to amend or supplement such Registration Statement or Prospectus, for the purpose of including
or incorporating such report into such Registration Statement and Prospectus. The Company consents to the use of the Prospectus (including,
without limitation, any supplement thereto) included in each Registration Statement in accordance with the provisions of the Securities
Act and with the securities or &ldquo;Blue Sky&rdquo; laws of the jurisdictions in which the Registrable Securities may be sold by the
Investors, in connection with the resale of the Registrable Securities and for such period of time thereafter as such Prospectus (including,
without limitation, any supplement thereto) (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required
by the Securities Act to be delivered in connection with resales of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company shall (A) permit Investors an opportunity to review and comment upon each Registration Statement and all amendments and supplements
thereto at least two (2) Business Days prior to its filing with the Commission and (B) shall reasonably consider any reasonable comments
of the Investors on any such Registration Statement or amendment or supplement thereto or to any Prospectus contained therein. Investors
shall use its reasonable best efforts to comment upon any such Registration Statement or amendment or supplement thereto provided by
the Company within one (1) Business Day of receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Without limiting any obligation of the Company under the Purchase Agreement, the Company shall promptly furnish to the Investors, without
charge, (i) after the same is prepared and filed with the Commission, at least one (1) electronic copy of each Registration Statement
and any amendment(s) and supplement(s) thereto, including, without limitation, financial statements and schedules, all documents incorporated
therein by reference, if requested by the Investors, all exhibits thereto, (ii) upon the effectiveness of each Registration Statement,
one (1) electronic copy of the Prospectus included in such Registration Statement and all amendments and supplements thereto and (iii)
such other documents, including, without limitation, copies of any final Prospectus and any Prospectus Supplement thereto, as the Investors
may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned by the Investors;
<I>provided</I>, <I>however</I>, the Company shall not be required to furnish any document to the Investors to the extent such document
is available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company shall take such action as is reasonably necessary to (i) register and qualify, unless an exemption from registration and
qualification applies, the resale by the Investors of the Registrable Securities covered by a Registration Statement under such other
securities or &ldquo;Blue Sky&rdquo; laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions,
such amendments (including, without limitation, post-effective amendments) and supplements to such registrations and qualifications as
may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably
necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all
other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; <I>provided</I>,
<I>however</I>, the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in
any jurisdiction where it would not otherwise be required to qualify but for this <U>Section 3(e)</U>, (y) subject itself to general
taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction. The Company shall promptly
notify the Investors of the receipt by the Company of any written notification with respect to the suspension of the registration or
qualification of any of the Registrable Securities for sale under the securities or &ldquo;Blue Sky&rdquo; laws of any jurisdiction in
the United States or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company shall notify the Investors in writing of the happening of any event, as promptly as reasonably practicable after becoming
aware of such event, as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue
statement of a material fact or omission to state a material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading (<I>provided</I> that in no event shall such notice contain
any material, non-public information regarding the Company or any of its Subsidiaries), and promptly prepare a supplement or amendment
to such Registration Statement and such Prospectus contained therein to correct such untrue statement or omission and deliver one (1)
electronic copy of such supplement or amendment to the Investors (or such other number of copies as the Investors may reasonably request).
The Company shall also promptly notify the Investors in writing (i) when a Prospectus or any Prospectus Supplement or post-effective
amendment has been filed, when a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness
shall be delivered to the Investors by facsimile or e-mail on the same day of such effectiveness), (ii) of any request by the Commission
for amendments or supplements to a Registration Statement or related Prospectus or related information, and (iii) of the Company&rsquo;s
reasonable determination that a post-effective amendment to a Registration Statement would be appropriate. The Company shall respond
as promptly as reasonably practicable to any comments received from the Commission with respect to a Registration Statement or any amendment
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Company shall (i) use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness
of a Registration Statement or the use of any Prospectus contained therein, or the suspension of the qualification, or the loss of an
exemption from qualification, of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is
issued, to obtain the withdrawal of such order or suspension at the earliest possible time and (ii) notify the Investors of the issuance
of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Company shall hold in confidence and not make any disclosure of information concerning the Investors provided to the Company unless
(i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information
is necessary to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required to be disclosed in
such Registration Statement pursuant to the Securities Act, (iii) the release of such information is ordered pursuant to a subpoena or
other final, non-appealable order from a court or governmental body of competent jurisdiction, or (iv) such information has been made
generally available to the public other than by disclosure in violation of this Agreement or any other Transaction Document. The Company
agrees that it shall, upon learning that disclosure of such information concerning the Investors is sought in or by a court or governmental
body of competent jurisdiction or through other means, give prompt written notice to the Investors and allow the Investors, at the Investors&rsquo;
expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Without limiting any obligation of the Company under the Purchase Agreement, the Company shall use its commercially reasonable efforts
either to (i) cause all of the Registrable Securities covered by each Registration Statement to be listed on the Principal Trading Market
or (ii) secure designation and quotation of all of the Registrable Securities covered by each Registration Statement on another Trading
Market. The Company shall pay all fees and expenses in connection with satisfying its obligation under the preceding sentence. In addition,
the Company shall reasonably cooperate with the Investors and any broker-dealer through which the Investors proposes to sell its Registrable
Securities in effecting a filing with FINRA pursuant to FINRA Rule 5110 as reasonably requested by the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company shall cooperate with the Investors and, to the extent applicable, facilitate the timely preparation and delivery of certificates
(not bearing any restrictive legend) representing the Registrable Securities to be offered pursuant to a Registration Statement and enable
such certificates to be in such denominations or amounts (as the case may be) as the Investors may reasonably request from time to time
and registered in such names as the Investors may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Upon the written request of the Investors, the Company shall as soon as reasonably practicable after receipt of notice from the Investors,
(i) incorporate in a Prospectus Supplement or post-effective amendment such information as the Investors reasonably requests to be included
therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the
number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of
the Registrable Securities to be sold in such offering; (ii) make all required filings of such Prospectus Supplement or post-effective
amendment after being notified of the matters to be incorporated in such Prospectus Supplement or post-effective amendment; and (iii)
supplement or make amendments to any Registration Statement or Prospectus contained therein if reasonably requested by the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company shall use its commercially reasonable efforts to cause the Registrable Securities covered by a Registration Statement to
be registered with or approved by such other governmental agencies or authorities in the United States as may be necessary to consummate
the disposition of such Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
The Company shall make generally available to its security holders (which may be satisfied by making such information available on EDGAR)
as soon as practical, but not later than ninety (90) days after the close of the period covered thereby, an earnings statement (in form
complying with, and in the manner provided by, the provisions of Rule 158 under the Securities Act) covering a twelve-(12) month period
beginning not later than the first day of the Company&rsquo;s fiscal quarter next following the applicable Effective Date of each Registration
Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
The Company shall otherwise use its commercially reasonable efforts to comply, in all material respect, with all applicable rules and
regulations of the Commission in connection with any registration hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
Within one (1) Business Day after each Registration Statement which covers Registrable Securities is declared effective by the Commission,
the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities
(with copies to the Investors) confirmation that such Registration Statement has been declared effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Expenses of Registration</U>. All expenses of the Company incurred in connection with registrations, filings, or qualifications pursuant
to Sections 2 and 3 of this Agreement, including, without limitation, all registration, listing and qualification fees, printers and
accounting fees, and fees and disbursements of counsel for the Company, shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In the event any Registrable Securities are included in any Registration Statement under this Agreement, to the fullest extent permitted
by law, the Company will, and hereby does, indemnify, hold harmless, and defend the Investors, each of its directors, officers, shareholders,
members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding the lack of such title or any other title), and each Person, if any, who controls the Investors within
the meaning of the Securities Act or the Exchange Act and each of the directors, officers, shareholders, members, partners, employees,
agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
the lack of such title or any other title) of such controlling Persons (each, an &ldquo;<U>Investor Party</U>&rdquo; and collectively,
the &ldquo;<U>Investor Parties</U>&rdquo;), against any losses, obligations, claims, damages, liabilities, contingencies, judgments,
fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys&rsquo; fees, costs of defense, and
investigation), amounts paid in settlement or expenses, joint or several, (collectively, &ldquo;<U>Claims</U>&rdquo;) reasonably incurred
in investigating, preparing, or defending any action, claim, suit, inquiry, proceeding, investigation, or appeal taken from the foregoing
by or before any court or governmental, administrative or other regulatory agency, body or the Commission, whether pending or threatened,
whether or not an Investor Party is or may be a party thereto (&ldquo;<U>Indemnified Damages</U>&rdquo;), to which any of them may become
subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based
upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment
thereto or in any filing made in connection with the qualification of the offering under the securities or other &ldquo;Blue Sky&rdquo;
laws of any jurisdiction in which Registrable Securities are offered (&ldquo;<U>Blue Sky Filing</U>&rdquo;), or the omission or alleged
omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any
untrue statement or alleged untrue statement of a material fact contained in any Prospectus (as amended or supplemented) or in any Prospectus
Supplement or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light
of the circumstances under which the statements therein were made, not misleading (the matters in the foregoing clauses (i) and (ii)
being, collectively, &ldquo;<U>Violations</U>&rdquo;). Subject to <U>Section 6(c)</U>, the Company shall reimburse the Investor Parties,
promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable expenses incurred by them in connection
with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement
contained in this <U>Section 6(a)</U>: (i) shall not apply to a Claim by an Investor Party arising out of or based upon a Violation which
occurs in reliance upon and in conformity with information furnished in writing to the Company by such Investor Party for such Investor
Party expressly for use in connection with the preparation of such Registration Statement, Prospectus, or Prospectus Supplement or any
such amendment thereof or supplement thereto; (ii) shall not be available to the Investors to the extent such Claim is based on a failure
of the Investors to deliver or to cause to be delivered the Prospectus (as amended or supplemented) made available by the Company (to
the extent applicable), including, without limitation, a corrected Prospectus, if such Prospectus (as amended or supplemented) or corrected
Prospectus was timely made available by the Company pursuant to <U>Section 3(d)</U> and then only if, and to the extent that, following
the receipt of the corrected Prospectus no grounds for such Claim would have existed; and (iii) shall not apply to amounts paid in settlement
of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably
withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the
Investor Party and shall survive the transfer of any of the Registrable Securities by the Investors pursuant to Section 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In connection with any Registration Statement in which the Investors is participating, the Investors agrees to severally and not jointly
indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in <U>Section 6(a)</U>, the Company, each
of its directors, each of its officers who signs the Registration Statement and each Person, if any, who controls the Company within
the meaning of the Securities Act or the Exchange Act (each, an &ldquo;<U>Company Party</U>&rdquo;), against any Claim or Indemnified
Damages to which any of them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified
Damages arise out of or are based upon any Violation, in each case, to the extent, and only to the extent, that such Violation occurs
in reliance upon and in conformity with written information relating to the Investors furnished to the Company by the Investors expressly
for use in connection with such Registration Statement, the Prospectus included therein or any Prospectus Supplement thereto; and, subject
to <U>Section 6(c)</U> and the below provisos in this <U>Section 6(b)</U>, the Investors shall reimburse a Company Party any legal or
other expenses reasonably incurred by such Company Party in connection with investigating or defending any such Claim; <I>provided</I>,
<I>however</I>, the indemnity agreement contained in this <U>Section 6(b)</U> and the agreement with respect to contribution contained
in <U>Section 7</U> shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written
consent of the Investors, which consent shall not be unreasonably withheld or delayed; and <I>provided</I>, <I>further</I> that the Investors
shall be liable under this <U>Section 6(b)</U> for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds
to the Investors as a result of the applicable sale of Registrable Securities pursuant to such Registration Statement, Prospectus, or
Prospectus Supplement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such
Company Party and shall survive the transfer of any of the Registrable Securities by the Investors pursuant to <U>Section 9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Promptly after receipt by an Investor Party or Company Party (as the case may be) under this <U>Section 6</U> of notice of the commencement
of any action or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim, such Investor Party
or Company Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying party under this <U>Section
6</U>, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right
to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed,
to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Investor Party or the Company
Party (as the case may be); <I>provided</I>, <I>however</I>, an Investor Party or Company Party (as the case may be) shall have the right
to retain its own counsel with the fees and expenses of such counsel to be paid by the indemnifying party if: (i) the indemnifying party
has agreed in writing to pay such fees and expenses; (ii) the indemnifying party shall have failed promptly to assume the defense of
such Claim and to employ counsel reasonably satisfactory to such Investor Party or Company Party (as the case may be) in any such Claim;
or (iii) the named parties to any such Claim (including, without limitation, any impleaded parties) include both such Investor Party
or Company Party (as the case may be) and the indemnifying party, and such Investor Party or such Company Party (as the case may be)
shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Investor
Party or such Company Party and the indemnifying party (in which case, if such Investor Party or such Company Party (as the case may
be)) notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying party, then
the indemnifying party shall not have the right to assume the defense thereof on behalf of the indemnified party and such counsel shall
be at the expense of the indemnifying party, <I>provided further</I> that in the case of clause (iii) above the indemnifying party shall
not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for all Investor Parties or Company
Parties (as the case may be). The Company Party or Investor Party (as the case may be) shall reasonably cooperate with the indemnifying
party in connection with any negotiation or defense of any such action or Claim by the indemnifying party and shall furnish to the indemnifying
party all information reasonably available to the Company Party or Investor Party (as the case may be) which relates to such action or
Claim. The indemnifying party shall keep the Company Party or Investor Party (as the case may be) reasonably apprised at all times as
to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement
of any action, claim, or proceeding effected without its prior written consent; <I>provided</I>, <I>however</I>, the indemnifying party
shall not unreasonably withhold, delay, or condition its consent. No indemnifying party shall, without the prior written consent of the
Company Party or Investor Party (as the case may be), consent to entry of any judgment or enter into any settlement or other compromise
which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Company Party or Investor Party
(as the case may be) of a release from all liability in respect to such Claim or litigation, and such settlement shall not include any
admission as to fault on the part of the Company Party. For the avoidance of doubt, the immediately preceding sentence shall apply to
<U>Sections 6(a)</U> and <U>6(b)</U> hereof. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated
to all rights of the Company Party or Investor Party (as the case may be) with respect to all third parties, firms, or corporations relating
to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable
time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Investor Party or Company
Party (as the case may be) under this <U>Section 6</U>, except to the extent that the indemnifying party is materially and adversely
prejudiced in its ability to defend such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
No Person involved in the sale of Registrable Securities who is guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) in connection with such sale shall be entitled to indemnification from any Person involved in such sale
of Registrable Securities who is not guilty of fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The indemnification required by this <U>Section 6</U> shall be made by periodic payments of the amount thereof during the course of the
investigation or defense, as and when bills are received or Indemnified Damages are incurred; <I>provided</I> that any Person receiving
any payment pursuant to this Section 6 shall promptly reimburse the Person making such payment for the amount of such payment to the
extent a court of competent jurisdiction determines that such Person receiving such payment was not entitled to such payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The indemnity and contribution agreements contained herein shall be in addition to (i) any cause of action or similar right of the Company
Party or Investor Party against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant
to the law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Contribution</U>. To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party
agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under <U>Section 6</U> to
the fullest extent permitted by law; <I>provided</I>, <I>however</I>: (i) no contribution shall be made under circumstances where the
maker would not have been liable for indemnification under the fault standards set forth in <U>Section 6</U> of this Agreement, (ii)
no Person involved in the sale of Registrable Securities which Person is guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) in connection with such sale shall be entitled to contribution from any Person involved in such
sale of Registrable Securities who was not guilty of fraudulent misrepresentation; and (iii) contribution by any seller of Registrable
Securities shall be limited in amount to the amount of net proceeds received by such seller from the applicable sale of such Registrable
Securities pursuant to such Registration Statement. Notwithstanding the provisions of this <U>Section 7</U>, the Investors shall not
be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by the Investors
from the applicable sale of the Registrable Securities subject to the Claim exceeds the amount of any damages that the Investors has
otherwise been required to pay, or would otherwise be required to pay under <U>Section 6(b)</U>, by reason of such untrue or alleged
untrue statement or omission or alleged omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Reserved.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Assignment of Registration Rights</U>. All or any portion of the rights under this Agreement shall be automatically assignable by
the Investors to any transferee or assignee (as the case may be) of all or any portion of the Investors&rsquo; Registrable Securities,
if: (i) the Investors agree in writing with such transferee or assignee (as the case may be) to assign all or any portion of such rights,
and a copy of such agreement is furnished to the Company within a reasonable time after such transfer or assignment (as the case may
be); (ii) the Company is, within a reasonable time after such transfer or assignment (as the case may be), furnished with written notice
of (a) the name and address of such transferee or assignee (as the case may be), and (b) the securities with respect to which such registration
rights are being transferred or assigned (as the case may be); (iii) immediately following such transfer or assignment (as the case may
be) the further disposition of such securities by such transferee or assignee (as the case may be) is restricted under the Securities
Act or applicable state securities laws if so required; (iv) at or before the time the Company receives the written notice contemplated
by clause (ii) of this sentence such transferee or assignee (as the case may be) agrees in writing with the Company to be bound by all
of the provisions contained herein; (v) such transfer or assignment (as the case may be) shall have been made in accordance with the
applicable requirements of the Purchase Agreement (as the case may be); and (vi) such transfer or assignment (as the case may be) shall
have been conducted in accordance with all applicable federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Amendment or Waiver</U>. No provision of this Agreement may be (i) amended other than by a written instrument signed by both parties
hereto or (ii) waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy,
shall not operate as a waiver thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Solely for purposes of this Agreement, a Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed
to own of record such Registrable Securities. If the Company receives conflicting instructions, notices, or elections from two or more
Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice, or election received
from such record owner of such Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any notices, consents, waivers, or other communications required or permitted to be given under the terms of this Agreement shall be
deliver to contact information set forth on the signature page to the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company and the Investors acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either
party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other
party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any bond
or other security being required), this being in addition to any other remedy to which either party may be entitled by law or equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
All questions concerning the construction, validity, enforcement, and interpretation of this Agreement shall be governed by the internal
laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New
York. Each party hereby irrevocably submits to the exclusive jurisdiction of the federal courts sitting in The City of New York, Borough
of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or
discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action, or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, that such suit, action, or proceeding is brought in an inconvenient forum or
that the venue of such suit, action, or proceeding is improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action, or proceeding by mailing a copy thereof to such party at the address for such
notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any provision
of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity
or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this
Agreement in any other jurisdiction. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED
HEREBY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The remedies provided in this Agreement shall be cumulative and in addition to all other remedies available under this Agreement, at
law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right
of the Investors to pursue actual and consequential damages for any failure by the Company to comply with the terms of Agreement. The
Company covenants to the Investors that there shall be no characterization concerning this instrument other than as expressly provided
herein. Amounts set forth or provided for herein with respect to payments, exercises and the like (and the computation thereof) shall
be the amounts to be received by the Investors and shall not, except as expressly provided herein, be subject to any other obligation
of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable
harm to the Investors and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event
of any such breach or threatened breach, the Investors shall be entitled, in addition to all other available remedies, to specific performance
and/or temporary, preliminary, and permanent injunctive or other equitable relief from any court of competent jurisdiction in any such
case without the necessity of proving actual damages and without posting a bond or other security. The Company shall provide all information
and documentation to the Investors that is requested by the Investors to enable the Investors to confirm the Company&rsquo;s compliance
with the terms and conditions of this Agreement (including, without limitation, compliance with Section 1 hereof). The issuance of shares
and certificates for shares as contemplated hereby upon the exercise of this Agreement shall be made without charge to the Investor or
such shares for any issuance tax or other costs in respect thereof, <I>provided</I> that the Company shall not be required to pay any
tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than the
Investors or its agent on its behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
If (a) this Agreement is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal
proceeding or the Investors otherwise takes action to collect amounts due under this Agreement or to enforce the provisions of this Agreement
or (b) there occurs any bankruptcy, reorganization, receivership of the company, or other proceedings affecting company creditors&rsquo;
rights and involving a claim under this Agreement, then the Company shall pay the costs incurred by the Investors for such collection,
enforcement, or action or in connection with such bankruptcy, reorganization, receivership, or other proceeding, including, without limitation,
attorneys&rsquo; fees and disbursements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Transaction Documents set forth the entire agreement and understanding of the parties solely with respect to the subject matter thereof
and supersedes all prior and contemporaneous agreements, negotiations, and understandings between the parties, both oral and written,
solely with respect to such matters. There are no promises, undertakings, representations, or warranties by either party relative to
the subject matter hereof not expressly set forth in the Transaction Documents. Notwithstanding anything in this Agreement to the contrary
and without implication that the contrary would otherwise be true, nothing contained in this Agreement shall limit, modify, or affect
in any manner whatsoever any of the Company&rsquo;s obligations under the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors. This Agreement is
not for the benefit of, nor may any provision hereof be enforced by, any Person, other than the parties hereto, their respective successors
and the Persons referred to in <U>Sections 6</U> and <U>7</U> hereof (and in such case, solely for the purposes set forth therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. Unless
the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular, and
plural forms thereof. The terms &ldquo;including,&rdquo; &ldquo;includes,&rdquo; &ldquo;include,&rdquo; and words of like import shall
be construed broadly as if followed by the words &ldquo;without limitation.&rdquo; The terms &ldquo;herein,&rdquo; &ldquo;hereunder,&rdquo;
&ldquo;hereof,&rdquo; and words of like import refer to this entire Agreement instead of just the provision in which they are found.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; <I>provided</I> that a facsimile
signature or signature delivered by e-mail in a &ldquo;.pdf&rdquo; format data file, including any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall
be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all
such other agreements, certificates, instruments, and documents as any other party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules
of strict construction will be applied against any party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Termination</U>. This Agreement shall terminate in its entirety upon the date on which the Investors shall have sold all the Registrable
Securities; <I>provided</I>, that the provisions of <U>Sections 6</U>, <U>7</U>, <U>9</U>, <U>10</U> and <U>11</U> shall remain in full
force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Pages Follow] </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, Investors and the Company have caused their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUALIGEN
    THERAPEUTICS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Kevin Richardson II</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Richardson II</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    <FONT STYLE="background-color: white">Chief Executive Officer</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page to Registration Rights Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Investors and the Company have caused their respective signature page to this Registration Rights Agreement to be
duly executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page to Registration Rights Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>5
<FILENAME>ex3-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>Exhibit
3.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXCHANGE
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
EXCHANGE AGREEMENT (the &ldquo;Agreement&rdquo;), dated as of November 18, 2024, is made by and between Qualigen Therapeutics, Inc.,
a Delaware corporation (the &ldquo;Company&rdquo;), and <B>Yi Hua Chen</B> (the &ldquo;Holder&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Holder has acquired, from Alpha Capital Anstalt (&ldquo;Alpha&rdquo;), Alpha&rsquo;s rights under Section 2.4 of the Securities Purchase
Agreement dated February 26, 2024 between the Company and Alpha (the &ldquo;Purchase Agreement&rdquo;), pursuant to that certain Purchase
Agreement, the Holder holds a 8% Convertible Note in the principal amount of <B>$</B> 1,100,000 (the &ldquo;Note&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company has authorized a new series of convertible preferred stock designated as Series A-2 Preferred Stock, $0.001 par value, the
terms of which are set forth in the Certificate of Designation (the &ldquo;Certificate of Designation&rdquo;) in the form attached hereto
as <U>Exhibit A</U> (the &ldquo;Preferred Stock&rdquo;), which Preferred Stock shall be convertible (the &ldquo;Conversion Shares&rdquo;)
into the Company&rsquo;s Common Stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;), in accordance with the terms of the
Certificate of Designation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;), the Company desires to exchange with the Holder, and the Holder desires to exchange with the Company
the Note solely for Preferred Stock; and,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and Holder agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Terms of the Exchange</U>. The Company and Holder agree that the Holder will exchange the Note, and will relinquish any and all other
rights he may have arising under or related to the Note and the Purchase Agreement, in exchange for <B><U>1,154</U></B> shares of the
Preferred Stock (the &ldquo;Exchange Shares&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Closing</U>. Upon satisfaction of the conditions set forth herein, a closing shall occur at the principal offices of the Company,
or such other location as the parties shall mutually agree. At closing, Holder shall deliver the Note to the Company and the Company
shall deliver to such Holder a certificate representing the Exchange Shares, in the name(s) and amount(s) as requested by the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Further Assurances</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such
other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Representations and Warranties of the Holder</U>. The Holder represents and warrants, as of the date hereof and as of the closing,
to the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
<U>Authorization; Enforcement</U>. The Holder has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this
Agreement by the Holder and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all
necessary action on the part of the Holder and no further action is required by the Holder. This Agreement has been (or upon delivery
will have been) duly executed by the Holder and, when delivered in accordance with the terms hereof, will constitute the valid and binding
obligation of the Holder enforceable against the Holder in accordance with its terms, except: (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo;
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
<U>Tax Advisors</U>. The Holder has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax consequences of
this investment and the transactions contemplated by this Agreement. With respect to such matters, the Holder relies solely on such advisors
and not on any statements or representations of the Company or any of its agents, written or oral. The Holder understands that it (and
not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated
by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
<U>Information Regarding Holder</U>. Holder is an &ldquo;accredited investor&rdquo;, as such term is defined in Rule 501 of Regulation
D promulgated by the United States Securities and Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities Act, is experienced
in investments and business matters, has made investments of a speculative nature and has purchased securities of companies in private
placements in the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters
as to enable the Holder to utilize the information made available by the Company to evaluate the merits and risks of and to make an informed
investment decision with respect to the proposed purchase, which represents a speculative investment. Holder has the authority and is
duly and legally qualified to purchase and own the Exchange Shares. Holder is able to bear the risk of such investment for an indefinite
period and to afford a complete loss thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
<U>Legend</U>. The Holder understands that Exchange Shares have been issued (or will be issued in the case of the Conversion Shares)
pursuant to an exemption from registration or qualification under the Securities Act and applicable state securities laws, and except
as set forth below, the Exchange Shares shall bear any legend as required by the &ldquo;blue sky&rdquo; laws of any state and a restrictive
legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock certificates):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY
THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR
ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
<U>Removal of Legends</U>. Certificates evidencing the Exchange Shares shall not be required to contain the legend set forth in Section
4(d) above or any other legend (i) while a registration statement covering the resale of such Exchange Shares is effective under the
Securities Act, (ii) following any sale of such Exchange Shares pursuant to Rule 144 (as defined herein) (assuming the transferor is
not an affiliate of the Company), (iii) if such Exchange Shares are eligible to be sold, assigned or transferred under Rule 144 and the
subscriber is not an affiliate of the Company (provided that the Holder provides the Company with reasonable assurances that such Exchange
Shares are eligible for sale, assignment or transfer under Rule 144 which shall not include an opinion of the Holder&rsquo;s counsel),
(iv) in connection with a sale, assignment or other transfer (other than under Rule 144), provided that the Holder provides the Company
with an opinion of counsel to the Holder, in a generally acceptable form, to the effect that such sale, assignment or transfer of the
Exchange Shares may be made without registration under the applicable requirements of the Securities Act or (v) if such legend is not
required under applicable requirements of the Securities Act (including, without limitation, controlling judicial interpretations and
pronouncements issued by the Commission). If a legend is not required pursuant to the foregoing, the Company shall no later than three
(3) business days following the delivery by the Holder to the Company or the transfer agent (with notice to the Company) of a legended
certificate representing such Exchange Shares (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary
to affect the reissuance and/or transfer, if applicable), together with any other deliveries from the Holder as may be required above
in this Section 4(e), as directed by the Holder, either: (A) provided that the Company&rsquo;s transfer agent is participating in the
DTC Fast Automated Securities Transfer Program and such securities are Conversion Shares or Exchange Shares, credit the aggregate number
of shares of Common Stock to which the Holder shall be entitled to the Holder&rsquo;s or its designee&rsquo;s balance account with DTC
through its Deposit/Withdrawal at Custodian system or (B) if the Company&rsquo;s transfer agent is not participating in the DTC Fast
Automated Securities Transfer Program, issue and deliver (via reputable overnight courier) to the Holder, a certificate representing
such Exchange Shares that is free from all restrictive and other legends, registered in the name of the Holder or its designee. The Company
shall be responsible for any transfer agent fees or DTC fees with respect to any issuance of Exchange Shares and the removal of any legends
with respect to any Exchange Shares in accordance herewith, including, but not limited to, fees for the opinions of counsel rendered
to the transfer agent in connection with the removal of any legends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.
<U>Restricted Securities</U>. The Holder understands that: (i) the Exchange Shares have not been and are not being registered under the
Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered
thereunder, (B) the Holder shall have delivered to the Company (if requested by the Company) an opinion of counsel to the Holder, in
a form reasonably acceptable to the Company, to the effect that such Exchange Shares to be sold, assigned or transferred may be sold,
assigned or transferred pursuant to an exemption from such registration, or (C) the Holder provides the Company with reasonable assurance
that such Exchange Shares can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the Securities Act
(or a successor rule thereto) (collectively, &ldquo;Rule 144&rdquo;); and (ii) any sale of the Exchange Shares made in reliance on Rule
144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Exchange
Shares under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that
term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations
of the SEC promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Representations and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to the Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other agreements entered into by the parties hereto in connection with the transactions
contemplated by this Agreement (collectively, the &ldquo;Exchange Documents&rdquo;) and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated
hereby and thereby have been duly authorized by all necessary action on the part of the Company and the Company&rsquo;s shareholders,
if required, and no further action is required by the Company or the Board of Directors of the Company in connection therewith. This
Agreement has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof,
will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
<U>Organization and Qualification</U>. Each of the Company and its subsidiaries (the &ldquo;Subsidiaries&rdquo;) are entities duly organized
and validly existing and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and
authorization to own their properties and to carry on their business as now being conducted and as presently proposed to be conducted.
Each of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every
jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except
to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used in this Agreement,
&ldquo;Material Adverse Effect&rdquo; means any material adverse effect on (i) the business, properties, assets, liabilities, operations
(including results thereof), condition (financial or otherwise) or prospects of the Company or any Subsidiary, individually or taken
as a whole, (ii) the transactions contemplated hereby or in any of the other Exchange Documents or (iii) the authority or ability of
the Company to perform any of its obligations under any of the Exchange Documents. Other than its Subsidiaries, there is no Person (as
defined below) in which the Company, directly or indirectly, owns capital stock or holds an equity or similar interest. &ldquo;Person&rdquo;
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and any governmental entity or any department or agency thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
<U>No Conflict</U>. The execution, delivery and performance of the Exchange Documents by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby will not (i) result in a violation of the Articles of Incorporation (as defined below)
or other organizational documents of the Company or any of its Subsidiaries, any capital stock of the Company or any of its Subsidiaries
or Bylaws (as defined below) of the Company or any of its Subsidiaries, (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result
in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations
and the rules and regulations of principal market in which the Company&rsquo;s securities are listed (the &ldquo;Principal Market&rdquo;)
applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound
or affected except, in the case of clause (ii) or (iii) above, to the extent such violations that could not reasonably be expected to
have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
<U>No Consents</U>. Neither the Company nor any Subsidiary is required to obtain any consent from, authorization or order of, or make
any filing or registration with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order
for it to execute, deliver or perform any of its respective obligations under or contemplated by the Exchange Documents, in each case,
in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the Company or
any Subsidiary is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date of this
Agreement, and neither the Company nor any of its Subsidiaries is aware of any facts or circumstances which might prevent the Company
or any of its Subsidiaries from obtaining or effecting any of the registration, application or filings contemplated by the Exchange Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
<U>Securities Law Exemptions</U>. Assuming the accuracy of the representations and warranties of the Holder contained herein, the offer
and issuance by the Company of the Exchange Shares is exempt from registration under the Securities Act. The Company covenants and represents
to the Holder that neither the Company nor any of its Subsidiaries has received, anticipates receiving, has any agreement to receive
or has been given any promise to receive any consideration from the Holder or any other Person in connection with the transactions contemplated
by the Exchange Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.
<U>Issuance of Exchange Shares</U>. The issuance of the Exchange Shares is duly authorized and upon issuance in accordance with the terms
of the Exchange Documents shall be validly issued, fully paid and non-assessable and free from all taxes, liens, charges and other encumbrances
with respect to the issue thereof. Upon issuance or conversion in accordance with the Certificate of Designations, the Conversion Shares,
when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights, taxes, liens, charges
and other encumbrances with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Additional Acknowledgements</U>. The Holder and the Company confirm that the Preferred Stock has been issued to the Holder solely
in exchange for the Holder&rsquo;s surrender of the Note and the rights attendant thereto, and the Company has not received any other
consideration for the transactions contemplated by this Agreement. Pursuant to Rule 144 promulgated by the Commission pursuant to the
Securities Act and the rules and regulations promulgated thereunder as such Rule 144 may be amended from time to time, or any similar
rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule 144, the holding period of the
Exchange Shares (including the Conversion Shares issuable upon conversion thereof) tacks back to April 12, 2024, the original issuance
date of the Note. The Company agrees not to take a position contrary to this paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
<U>Governing Law; Jurisdiction; Waiver of Jury Trial</U>. This Agreement shall be governed by and construed under the laws of the State
of Arizona without regard to the choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or therewith or with any transaction contemplated hereby or thereby, and hereby irrevocably
waives any objection that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action
or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY
DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
<U>Severability</U>. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability
shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
<U>Counterparts/Execution</U>. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party.
In the event that any signature is delivered by facsimile transmission or by an e-mail which contains an electronic file of an executed
signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
<U>Notices</U>. Any notice or communication permitted or required hereunder shall be in writing and shall be deemed sufficiently given
if hand-delivered or sent (i) postage prepaid by registered mail, return receipt requested, or (ii) by facsimile, to the respective parties
as set forth below, or to such other address as either party may notify the other in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company,
  to:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen Therapeutics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Kevin Richardson
  II, Interim CEO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: 5857 Owens Avenue,
  Suite 300,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carlsbad, California 92008</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email: kevin@pridescapital.com</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to Holder, to the address set forth on the signature page of the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.
<U>Expenses</U>. Except as otherwise provided for herein, the parties hereto shall pay their own costs and expenses in connection herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.
<U>Entire Agreement; Amendments</U>. This Agreement constitutes the entire agreement between the parties with regard to the subject matter
hereof and thereof, superseding all prior agreements or understandings, whether written or oral, between or among the parties. This Agreement
may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written
instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no
delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any
waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of any other right,
power or privilege hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.
<U>Headings</U>. The headings used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature
Pages Follow)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUALIGEN
    THERAPEUTICS, INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Richardson II</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>YI
    HUA CHEN, HOLDER:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By<B>:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>/s/
    YI HUA CHEN</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>YI
    HUA CHEN</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notices:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for delivery of Exchange Shares:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF DESIGNATION FOR SERIES A-2 PREFERRED STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>qlgn-20241118.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa+I2bP9z5Z8qekhvWB5bZm6/y4lcDUedSH0/m0WMdAI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:QLGN="http://qlgntx.com/20241118" elementFormDefault="qualified" targetNamespace="http://qlgntx.com/20241118">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://qlgntx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20241118_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20241118_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>qlgn-20241118_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>qlgn-20241118_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qlgntx.com/role/Cover" xlink:href="qlgn-20241118.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://qlgntx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46103126516240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 18, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 18,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Qualigen
Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001460702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3474527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5857
Owens Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">452-8111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QLGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MB7)C5;H/!H)4R-TG>]DGXIB <!\0%MR[&Q64U\RRT4"K+='N:E!S!\54BVB
M$]*MRLQJ^%9 G!U-U(;K@6]!RIWPHWW8U2XL/!#VH#;GA/9/21B$[?^&^T!0
M8H0E1ECHM3 ,\M=X8:R&A?J[CFBGT*Y7<-5[:3(6\:$'Y6FXWG!O],M/M!O\
MBO"U2KX6ICZZ5E$.M6C)_#7C=7!X>/_L*P+1+B':J,H8".*"XC9AJSH*/'[)
M$L,1CD[)T3DN&5.NA8K)C8P)%%]M7G"ELHR:ZJA;HG51P1MIA7TEMR+AY"%/
M%_6UC6L$ 3UK]=IA'^'IE3R]8WB>^4JXRH:</;"T-E&XSE/.$K'B\F2^YIIE
M/+<B,J?D3D;G"&6_I.P?0SF!-=4L =68OY"O_+6.$U<*('GM;M +0@3KHL2Z
M. 9KSE[(70QL8BDB5GCYX:7%%</N6:O=:W?"'H)'@\H[@V, 8164SI0NV$[)
MS,*S0)0F$Y5#0B&O*JY=\@;UZQL,\IW!TV,@QW$,M@@ULS\@]W =>93U9+AD
MI]_IG3QNH3>3\8;+'#,56K4 BCHX#CK?JEI07'*6"UB*5A!@@%4/H+B+?P2<
MN!&L\UQM92T<+C=A.C$+%F-L56N@N+=_9"N+<*K51LBH?IEQS<D80ZNZ!<5-
M_B/:5!D++O.GR X_&;CB!>PY,7>F5;N@N-<72SB&[>QA%%S@4Z\;?,90JDY!
M<8N_5Q%D9;I6$FM=#2)@;6=]2BE&5'4%BIOY=RVLY1)2DZ:YW'NOJ:7"A9HV
M'K3J"!0W\)E*1"2LD"OR#0I<"Y;4\N J33QAU0%"W*.GFI]%D!X.3]AN?PA;
M--C)/BZ7]>O7H-=(5ME^B'OT_\CNC,F!K!$0EVT$?+?CQ[UY+BQLTM22T/#3
MXC.9\2B'>JO=<S0HN?I4\H3 W\RJZ,<IR9@F&Y;DG/Q\#CL2DL&,S9IIE+SJ
M R%NW'/-8E>!L]=TH6KKKT'@Z?[+ T92N7Z(._1;TLC-2[1F<L4/;B\;A![&
ML^OQ$\94V7UXE-W?I%RO7):^@()=.Q/)F*Q?7ESP8,GY[UY[W4\(WYB[HR$)
M7X)0<-X#7;U[*]\-K,J*-^&%LO!>71RN.8/'P5T WR^5LF\#]W)=_C8R^A=0
M2P,$%     @ 2(%U69^@&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M
M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>Q
MS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G
M55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4
M)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(R
MA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[
M##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R
M 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[T
MH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<
MO(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q
M]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**
M==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9
MQP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR
M'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<
M8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)
MQI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY[
M'R73>RHY_U=3_ 102P,$%     @ 2(%U69>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !(@759JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( $B!=5EED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !(@759)!Z;HJT   #X 0
M&@              @ ',$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !(@75999!YDAD!  #/ P  $P              @ &Q$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #[$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qlgntx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>qlgn-20241118.xsd</File>
    <File>qlgn-20241118_lab.xml</File>
    <File>qlgn-20241118_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "QLGN",
   "nsuri": "http://qlgntx.com/20241118",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "qlgn-20241118.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "qlgn-20241118_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qlgn-20241118_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://qlgntx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://qlgntx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-24-047143-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-047143-xbrl.zip
M4$L#!!0    ( $B!=5F_(]4]8X4  %'  @ )    97@S+3$N:'1M[+UK<]M&
MMC;ZG57\#SA3,[ND.K BV7'N;ZID64YT7L?6EN3)3NV:#R !2HA!@ % R9Q?
M?]:U>S4 4K*CC)V(,U6Q)(*-OJY>EV<]:SSZ[L>+GUY^/X9_CP^?P[\1_N^[
MBY.+E\???_<9_PN??B8??_?L]?-?HO.+7UX>_Y^_S:JR_28ZV%^TT44^SYKH
M5783G57SI(SY#W%TGM7Y[&_P1?CJ:>=[CV_[WK?1/*DO\_*;:/_;J,W>M8^2
M(K^$7Z=9V6;UW[[_KW+2++[][K/3X1?<VK&U+ZCSRZOV;]]_]^S[XW=7^21O
MHR=[!]]]]NS[M>_ZA >C+X#1G!\?O3D[N3@Y/H].WYP=_7AX?AP=_G!V?/S3
M\:N+C>/[O:^7O^5EFF%[^WM/\_(/'/.ORZ;-9ZOAMUY<Y0U\?[JL\S:'QD^7
M]?0J:;+H\++.LCD\.A[MM/C0?Q7I;\OJV^_>?.\^^NZS-]__5TU_WHW@D31I
MLS1*FJB:1:^JZVP^R>KHX*LX>KS_^/-HDK4W659&_[W$CL$/%U=9G2RR99M/
M81 GY70OCI+H>58D-TF=1=.J7E1UTN95&4$7LO'(=^&HFB^2<F4[ -\MTRA+
MIE?10@911SD.-I_ET"UH!1J)&IB3I%U"^XOD$@8,?<C:*MK!+\917DZ+99J7
MEU'>-E&SG$ZSIJGJAMI.&OQR$X]'B9D-G;':=(8>GU9%D4W;_#HK5C&]>^!+
MC1W"WG]Z]>$8Z+;[ _<[O0<&?79\=')Q^/(<A_P'O7#C:#_."?OYQ^.SX\/S
M&';3Y%?8#Q'L-MP,,#'S!K82[90RS7&?PY;+VFA6U>T5;,6(SIT[;;2I8&LW
MRZ2D5LYQ=\&V_GPGV=UYO(NG#ALVI_D07@=_/?CZR9,8SV4"[:1P%G;"W>B_
M,1[!5_JGZFQ99-'3_2^PL;/L<EGPJ7P>+>IJOBPNZ=RW>)26T'[-NUW.:)1F
M35Y#9Z#'>=,L,VJQR8H"_T+GU9T&?X;'(_/')KL&25$4*_JXK-KHURHO6SQ6
MIG$]]=$,.F5[@ VX*9%)TL[!I,PK$ :S)38/K4WK? *#D=F'^=#IIT/]P+8L
M;,PVFZ,4+K-JV< ,W>0MK W.8/8.)I6V 2Y*FA4@Z.H5SZ_=MG%GC>GQ8 EJ
MUQC(7=,8_1K5V67>M'(/D#("^SBXG-Q6/K./GO&CKA]^1\-!;%HX0SEMJ9SO
M!3AT\RAI6^@K++_<"K [5.EY%MWR)K-5_*OL<;VYRO&*2>85C*O"TX(S55XV
MX7&YR>%DT !I4]?5-5QB($GK-H&N#LT&K@E\T"Q8NO#RG%_!O#9TZM-LEI<P
MJ$E65#=Q1$=T2%+HPM1PVOG&J]U9;]8<=;X8%XLBGR83$!(PL6UFSMMX!+=Y
ML_YB^W!=\8/.S9 R]KYGZ5%;+>!%B];]85*U;36GO_WM^X@O.Z-*AK?=7UZE
M?/7Z9V@&1<B+UV?'H-B]BHY>OSH_>7Y\=GAQ\OK5>"0R>+YL014$(7.=E7!&
M&A(W"6W5WN7'-P,<4CDYEU65TI^NDV)).P^^W,!)D:-!^SB;9OF"]W629K\M
MDRG))SJ(*';&(]S'$Q!!T[=E=5-DZ666AJ?1Z91&?M'9A',U P6ONFF^^50V
M]WVJ:X=G%R='+X^CD[T_7C5\?OSBY-4);HWS/ZM=N7&]#O8.(I (SU$,LYJ'
M,F$/+![8EJSX@<PV6J&3V%G19#>X1_L'XIL(M+YHFBSR%OKP;Q3*]-7V*FGI
M2D4UB<[*30XZD;:(C4%;5\EUQF<P2TJ\@Z)+N'&Y&V#U7$EC<C<>P>4#1M04
M13N<G^<9&U%DF)G[A=L6E7%GLBOW*AX2O,JYR?Z;^RJO*+;C$<S<G_ET\?^Q
MV?=YO[>SI[\M<]2"0!D&2[$JK8797('VTIM-$$NBP-J%Q(EUQL+>E_=S&W_8
MX#ZAR<7I,#,Z'GWHE#[9.]CY=8/Q_I!F=3;+BQSD1#"Q.).H4*XBWL<DI,!V
M \MM"E9<!+<ZM*B_M5=UM;R\BJHRPT_(/,M1?L^S-$_J'+N-FD)=%0U]M=%?
M"U1R5_(W5D^GU1ST;7U@/")=.9%^D'9LQ!V*S67#ZH?8Y:!K+^$/W!B9P9_O
M/UVK0M^/ ^?/O@<&W(/O?[CPH=,Z2^:@V_UEIA5%P5U>?A#.Z+,?CPY_UV2R
MC\<)J]]^VR4-Y%/8+<^JI$Y)JZ#S7P4>414=.,B)/ICJ@QU?SE8 XW0N&]#%
MFB9ZGJS6R. T6479NVE&EM$J.D=O./PMYM] M.G/^"#;2B!.DVB6H7551$5V
M"?^]JHH<'Y"C^@8T6]AXYVC^DU36!F#+<1N3I'Q+NDP.0C5OE^Q5D*_3]RAL
M !/T2U6_)5F<+-NKJB;E%EJL,U2'6,07R4UD;,'KK"Y1XD"_$M[F< *F1=5L
M$!T/:%,8_9V,;Z/ 6Y72G[4-"C],[ 2T^ASOVD6=PR*(Y7($TXU":++JN+/@
MPI6;LL[:A%V$M-[2%P[WQ($C#CZ ?JOOC81?USGWR:PL].#_>?0H>I%G1?I-
M=)I<9M_":WY;9N4T@]Y\&[U>T%[_!KLC8OC;Z)])L<2/HT>/)-3\W?.3?^I(
M.HZE+_#:F%0U'$#WMV=%,GT;'<!8&SR*8$E?'#X#B_WH^.7+T\/GST]>_?!_
M_K;_-_K]_/3P2'^7-TAK&*1*%@WT1'_Z%I8L;:]PA^[_@[UCCQHX@[QE\35G
MVL8U;I-I4NBDM=4BG,4BF]$WGF_ROYG7P;-F*G42OXTN5@MX_V&=3/+IM]&K
M9)[Q1+^J</H.[)<^TV_A)]]]=O$<_W.&_\'9@7]AE@<F? *JQMM'DPQV'[2]
MH$6T[KXO:.BGX?J(Q\]OAZ!UVRGL+*_T'^%V^*1D#8N!-9?X5(2$W-PN9$,A
MH:3(!F)80Q&OQWL'G\SQ_P0F&R[[08L+9_*B3E)^Q-S%J#W*3,/G92.7YO-J
MNL1K5+PT$XS6<V0F2VU@AN]@_+;Q_"^2FM:K9?%,7J#Q"-]DPIL+],GB8' U
M=W)V$?E@^'_5#=U$U02F0>(.& 1)^&WGRPEJN"1.H\-YM92@Z$XN+<FE(\TT
MMAUR;4G_.UN,KAYR\DZA%[$9? /?;1@]4$<W"7PWW>X[AE_,\Z;I.E#\K@O5
M07.:<;F.W\%REY>T7-+,=E9E5F%CG[?5].TZ^<F/-/A(Q_R)\012."2+_KZ_
MM[]_$"U@JS=7I%Q1# 34,=:8IT72D/ED N-YJ3%*MAW-1W,X?WBJDQE<V./1
MA$(KV$2N9X,7='LXNLLX'AV#T0*+@E*UKVOCBJS')E2UDWJY>+YD@6ZJ99%&
M"&UJ"W8!@#DF+JDZPV8J,(3(7(H2,O- _,%@(]LW@W:*24VOEFU4Y/.\)8DI
M-F V:6,4V[.L1KG?\#<I\AQ'U8*?! 6^QBO:F60Y.<X(M4(!"30@;3_@2B#E
M$2\.VGCP3;AIZFG>T&5"O_*FHM]!+8M=ZQ30D,$W:T9/L;]KV/AVQ-OMZ:%S
M,#'+LLF* 4%S#ELL*_^=)] 1$!,O8%)1GSY*ZGE61&!=\':![0HF(G2YJ*8,
M_&NC@X.OGD:'UUFY=*K<X1SZ#Q=K'#TY:-IH5E2XEFKGPT^_H.K_Y(OMXM#B
MX+EH*/AU"M.6_9Z0SV9+?CO?G?EFQ,QVPO_0"7^>-V@#+A%\<8[>',0:W4=<
M\\G6)*0)/I[-&'0\'G6LPNUV_@-F6TV9$#9K579C_-BG!9?[N<7EQA\$P=LN
M!"U$-H>WG33H*YJN<X;D\C%./L)GR#@BO=NJB:1H+ISW 1HNJE6&G6:-IZ8
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M6"#DB!*KK_C@]))$&RBX0RQ>SIN5,*D6DSPNDCQU63H;CINRN)D3-QZAJ;0
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MQ$WP8BKL"B^"2U#DA2\/P*]S'%'HLI-DWX&Z$;0>EKZ+XS9)4Y6P5[#F*Y9
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M&RN).:"ODQ0[IV4=1&?YH+4Y:AH42/9'3;,ZM,X=\R#C-F2O*%=76,G.0S_
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MN'F79-[H9' <8YYVY#0J'0]4WY\N3A'&GPBES/Q^@"*?^&K\[?O_?75\@AK
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M'6\2X/[[XWTP2CO/$*7FSM/N+4[&AMQ=/*F2TWNYI%5&A_(RV_5S:MOTILK
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MY.H9E"#6HI)K3Y!4*.E=,H9+*BSA5')M'';=N 1%UY<]+,I-:LUU$-+W4(
M%8+]9/!'6#1=O I[BW2F"&L.7B.0(@&1E&-]=+ZM7,LBURE7&]H@ XK&K@XN
M4VS+F-@KS52!)ZC*!1%^-IDFWW3> OW7+;%K<D%H(O2R4'@1E8F7%@:&%.(C
MHAMDI"(Z=JG>T3XP%R:G>Y]3Y@W3)_')/)%H'X)DXS".R.DV'$:4*I:#H?P<
MW2@%6[_"O4F6Z'R1$?8D4&79G097&.X@.!L%V9Y@DE=Y2NP\RU(4 [PQ^9YF
M(@")59%YR74WO-9@LX.8\=-UV&)G CG.K3JJD^[^XNN '\T1!ZT)KAJOBR7:
MR3 %&5%"'S@&LM#+%/"OY_5=B#!F.?H3J%?,O89XAH+\!22OD!:7&3.F5WDF
MMQ*=%]+K7:&^8N4_$6K21/32KG7N,-/_?WM7V]LV<H2_&_!_6 0M$ -"?'F[
M.[BI<91,VVP4R97D\QE%/] 2E1"A196BG'-_?7=>=G>6HJ0XM>*7^%,<2>2^
MS>[./#/S3*TXH"(GIE=+$$L V@E:!J=S>A6=C) );1WA!DJ85,^)-'$U#:^Y
MGA0>O/:&<'* ZB,* (.YZR7 ("=^[KKESH6&^49R)2)LUY?*JO)$]8[9H-9X
M2E\^>4IOTU/Z\LE3>F<7V6LF(QMRO KL=BCC-2KB+Q!DA75UZ'+K5$FS)]=D
M*MMXCTE90!J<4_4!5)(I-J8P&&M:1#OGF:L[$E=:P#"%AZ>!VB6FZ/AA*"94
M9F8*WC14DB6,58_TH4=T&/G4*XU39R%7PS?4*">D2E_P>NXSY ?$<F!DF=))
M+6UG0;EN2EB5?&T:SQD3/56\;UQN=IA29[_PBJ"Q#HT!/3(">/HJQ'FADB-,
M&83_HI.T/O'(JV8$H9E7,?$;Z=_(.3+S1M2>.7&B0]_!$V[65)M]B%L2)2UT
MCL.P1-8ZNR._,M>H)FZO<!**_W=5R5:%#W)Q,])[1**DF^?%.FIZBO2<S@M&
MT^H9DBHU:2D:BY8K&<G. ?)/L;)>/C:WL)"R9@83?_P(?HE2!'Y-"XPT9HX7
M*946=*3._CA*^!LZN[2RY5#I"I'B]A8#:A6F,Q'KRO"E.95D$=*9NM365D9J
M:);/@$VZU-N B3SU*_)KWL&57&'BUP4<%>DV86<X!BU /TWU! (I+PBXY!QA
M2A2"[3L$WU;&I6X,6ON\LCNXC_HG.PW>H%F:S)5-2A)OQW= CC%P $WT>BR=
M%\$GRTF]%+(/X0H&\!49T;;Z4%Y<5P74J(9$0:N_&9=V LF)R%G9O$4G! NO
MZ2 ?W<0HG1;ZR(:;"7!D$;,Z-9BLLP=*='^3/4T(H?-[;&\-M<QI$<5D;N9:
MW0&O1#Y,_:*PLE8X[W\GB#\B4O66=N-E,C*;#Q 6@RQC)AT!-V"PE!GC.S8:
M%FQ(BEGQTJ8PI=ZR-Q%*+HE!( 7%H#&V^$4BZJ_*_'FP_J1@FLJ LD>&)=S<
M[;C&ZY@[$0&U 4=@R[,=E$^2$H2)NX;W.BH08/J.])U##-:7 $_'8O]?XV9Q
M</6%$6'CO7+LRU+?\#2OY;YVYY=C'F$, HK1P<L<(LM\<7C9U$V1#$R6M>(_
M22I\9**&".H1NH3 HX[FJ3<?/\Z6P3A%4VFMGY0J ,#5A.$LIAQ)V;V,/Z.*
M.S6%V@I+4KU(=;XB+\EINWCD"CV:K'%B 7-*M0@N*ZU7FLDBR-^WV!]V<-OZ
M>.;(]#S*A0AR+ZP3S-YZ<8$T^B:*'X,"!$A4P4:P4,4\,QU!A9 891J(8,4P
MT0US>D!DD]:?D13M8XZ)L^0B)T9N+_],OPJ&/&I D@.J8Y(D#9&2O$BJ2AK0
M\NM[:U8FU&IBV/>J@4JB&B7L#G<U-7PCBMU5B#9>Q)//Q7Q:#OET7*@1@I\.
M28&%M\)<ZT%1(8D*(?B.89[UQ,]+.\ ANNWM=CN*BK=J!B'&Y>(@,II'4AC2
M9"1U\"O,L6%W-^1XT$E6"RE*R-H(W:=X9(Y7R('F@J]ULJ:%(!^/S0,J'S+-
M^H.D*%EWSOQ"%2WG!</4WM$"-AO>2UHR8*+!S-7VI:_5,B#I!VMH72R=E:0>
MPL)G2<SHK<QB$5P:7'V $ $$C?$%G#RF[R+@!'-P[05?C1E?S4C3XX4%0NU9
ML%VQF,&XH>8P1HK\^@)=OL)S+": >9*CY$MZ70=0IA,2,- M,&+&A-?8D)I:
M-[9$.TTP596=Q*,%DGYZ9LLHS(WHMGXMY%&+P(A0R)4PS+)3O\'Q,\F?F*B9
M\1J/C//;1?>2ZH3%Y$75B-KH@.6:QUA>"ZRCL&<).:<Y)=#%TT/8)@/6S&2,
M@7A0:0C9/07[] (?$AZ@(O17;X(/S(;<T\_*8FPHE(U%G J>!DCQ8TZYT.BZ
M0(^AB0?!A>3H0I?26-@L,_,9FF87>6D4TTL"L)RI/W*B1A?"3%LT*^;(: 2.
MN93ED,]CVC-@ *U;%)YC/";E!!EO!$N$R6T4:\'"I@_C CD!9?]BR"JW.CL%
M\+BU6<7Z2B''Q#;.A4_,?] I$F.,CTUZQOCEC.-&X06 6YJ24R[MCUL4U#=T
MQ(&163L<M6(TQG* %\@I\X=(6V;)3C U@IV['+MF;DXM=5_B0LND5Q^-WFY(
M"_26)5X[/',\P4=?I#U0](GF6<CN3&ZX(1(L 6WQIO8&EG)YP$K2[X*J68T<
MA-OH0@OC! D3#'105Q5.1B;1E4V]<9G[,$+A5G.-\MK.)]A%#N*%0G%QMF"<
M^!U")B6KU"UH;23K>(_EH"U,1IFM)<G=XZS4<AG[E %1[W?RWZLGE]9MNK1>
M/;FT[DS;_=64(9XF^)U>';X\M[<<&L3[4W4%? )W%#J\1-)@)12RDJI5J[()
M!Q($^Q _JT56D)U5<K,NYE17\J$;_&R]W\)65)-QJ":FW$-H"@JM]$ ;NJ+6
M]V'-2)?'S0J#8'E*0H.B,B:Y+7J',6D+FK3%,5R"0FEXOFK"<T5$<!4*G'&N
M R0G?$JG#0P%89@7+&O QW&E(++;L@K807Q&Q]R8D$.JS6K#N4"1GC/CIX5M
M9-N%MU1K:-Q94BJ,8/Z*%0MI(NLJL$KLTB<4=O,H4='4;2=P9&G#H$R&AAV9
M+!H'# E\MAZU* 6K0)%BS"?\9#$8"J"5N4TS6^T.IHK??BJNHV8=^UB+U!ST
M[V"EB6,_=I U4"^;0&840V?V69<;%R-XL;U5F45;==+&Q=(ZF.J>MCP!90N)
MPIOD2[Y*$]*932F"=0E43)LG"U6BYL%F #.XPMQ(CA8O*) XE:'1Y<8;6Y@N
M77JQ6B0#,(0K =5W[-.D,3TL=0RQ!DL'687LC07BK%,1]6E3 M@TH3A260Z"
M#J*Z$H)<W$>$E]:>W^E,+>/ZC.7Y3-6*&_:,7_)0I6+K##4<4OX%?;=Y&%NY
MS-D*%9/R*#$JS$1LIUI,$-%5!^0Q6>1LKJ5U+9VK#]TPB%'8=QGOBZ7T,P7/
MB?9LG7V<SCS2&6TT+(3G2LEP)Y"EK&5^=0Q89!ME>2]= H/IIHN:QF<KU>N9
M Q;,5GO="#<I@IWHCKSV_ !<>M3DZ'SME,'M-9H3$*NGG(BG*?[;=9/\UH\4
M3GU%&1"@5([B:WB;%B#\XQC,'OA+&[KE$.E<P0R'!<EB@H6T#0M:!<ZP4].T
MNL-,I"A$%FDDE'::%EY2(.&&\D@U_E$O)-?Z&55SKN]8L%61&]#%&W%#AF 9
M=2YSLU$C+K4 /3.6A LI&#&EFRY$V<+C7'1,Q&B)Q&?!55OC^14NZ$O8*[NT
MFGY.O+GU<>/0G<_(*_@E(,!^"H1-<ZQXCH%)5RF75EY2K)+J!G"0!P=\3T#;
MSU0QSQ).:K9CL%X>\JC8)(CX\B+].&<.(V+8(%LCS]!!(VK!CHIX7+H\+;^4
M,>?Z6G?T31+"66&SQ$V6TM>+*V!G/RJB& ? KCX.1\.0*(J=LI66:DM"+D?(
MG4(LH[Y&("_X]1A5&N2?PA88N(-((8@4FV9:H=,' OUWE"( -IHU^/MAKJ=Z
M(NQ/QGXY-M+3Z=U=4ZG5A]XKP8)J.#Q]I>=Q[LM7ZEUS7V_-LR#Z/>RI[J'Z
MQVGO7 UZ4= V(6 =%73.5= :1-V.;N\T&C14MZ=.>MU6& (LI?@G^M&H?Q#A
M#U6SUST].AZHYCE^=Q+T!OJOHR#J] ?X27=PK%O$S_5@CD/\,PK[*@Q:Q^I]
MIWNF7]V&IP]T X.P Z\-VNUS+0Z#+CYQU N#0:C?%_X!WZN3L/<A&@S" VSU
MY*0=M1!":P=G^GH)>R%\W.QWVZ>#4+]'G79:W<Y!9%^LHEXO_+T+#U&[X1\G
MO;#?U__#">JKPZ[^@>XV3M#V5A,'??Y";:C$P'>LSQ#M/^_;/*43U%X.D=IV
MY]UN](/PJFLY/HL&';WBZ@S$I7O8D&DAQ#6ESR^\<=!"&RG#>6?"'HVEX3,&
M ; "199M#@F!"OZ%)BLPXU+D&)0;V[,+3R:L@ 16&;(=P'URD5_=\Y2/UT_X
M^&WBXZ^?\/'* >%$02Y]531N?'1YDK%4@I[A!*R6DV=FDK1LM+K0R\[?G[W2
M,WS8U1>7Z)@O>\W]?YX&[>@H[,"%UPM.PM-!U.KKFZK3XC(Z\ ):=]O"FK>:
MN:MY\B9].]T/!(4XE038HR(<[LTHBYN:GA4#>1!/?L/D\*]8,-_^==T4-:_W
MZA?:/Q:7'+)V![QYL[:EW=FN>J]-K(GJI?H&+$80CQ=%*UOGM[]:^_)5(GO3
M*0%* ,A%!U'=4U_SSJ\8_6<8^6_:5!HELV$\3<LX>Z&MD_]OM=>TB??"MTCB
MUR[3(]U$:YH8@-_FF^8U@@L^O52M3VDR5LP[H16[+O%[W?5,W:,YOA_#>AA3
MZ5V(_.D&-*HSC)]C:JL<6.Y2RHIC.%ZX@RG7<8?Z4N9[I(9MJF-]W8]D\M\T
MUH]K9>.0 :I67%PFF=(:WF:;?_GRU[<J((8RML."2_WH,-;O>/UR5JIQEN?%
M9COA2/ ZYZ".OO[YEMI[MA^4I?X#IY:FM*'"V7]>D'9_2YMD24=O&1C9U.1[
M"L.*IK['<&[2AF^H/:(%*88HJ+_-BO'P10:LJYN9+W=6LS']P&*]#+CWKU[X
M(8@Z!X3PG@1'H8^HJG9X.%#-=M!YO\%>]*.C3C X[874@T/ D$][K>.@K_MU
MV&VWNV?]?W^_.JVK\*HW3WC5;>)5;Y[PJLWO<;>7_(W65X.NLBA2/VR=]B+T
MLY@'MK>"HUX8?M#GP2:VWQT[N99A^A0*A31Z''MQIX"^LGC^]M8:0/^!NEP(
MK_ J9.T]9'%#GYESF>EQ!6ZY^[S<U]YXP9/VP,=LUK!NK ]\:(C[/-*QH?VB
M#%Y_XS'>YPO0MK#HC8"#^K$<-G)T!X)$5=Q4<K3J>3JF0")BG)UY]5X9P'G@
M4U)3PG)/_>6!C\E&6-51<E'8TO=<ME56TMN5MA%JY3^!8?18C27/,#+S=HOV
MS,+,_?2#VSCOFOOAGY_2B[14P<J(JUMIR@QGT^VT)$?76!_N9"M@D.P=C''5
MCO_Y:<<_[7AI 7V_76(V?O/Q;'RL^JYW? ^+QW"6 F70.K#AWIT!O_Q-=5'E
MFNVI-N1E/!T)-SL2[GZ#[C:[!^?@S-@]'GQHZS_^!U!+ P04    " !(@759
M T<T%1I6  "K0 ( "0   &5X,RTR+FAT;>U]^W/;1K;F[ZSB_X!-9:;(+5B1
M_,C#\4VM+"D3[74L7TE)[M36UA8(@A1B$.#@(9GSU^]Y]0MHD)2CV(K$6W4G
M%DDT^G&Z^SR^\YU7/UW^_.:'X>#53R>'Q_#? /_OU>7IY9N3'UY]Q?^%;[^2
MKU^]/CO^9W!Q^<\W)__QQ:S(ZY?!P?ZR#B[315(%;Y.;X+Q81'G('X3!15*F
MLR_@07CTW6V?^SY81.4\S9_4Q?)E #_7'TR*NBX6[F=9,H-6][\/ZN1#_23*
MTGG^,HB3O$[*+WYX]>/9VTO[_4]FT2+-5B\W]8!^6Z7_3KC#7_SP]WQ2+;]_
M]14V"#/T[E..;>]%FKOC*]/Y52T?I?DTP9<_H=_=Y9A?O?[AY,-5.DGKX>#9
MWM-77[W^X5--P$-:S#]W++!(KW[YX;]^.7QS^H^3M\/!Y4\GYX?O3GZY/#VZ
M"(/3MT=[K[[ZY8>'LG;2^C2)BS*JTP)>D1=Y0M.@5O5AC)2&='1R?GGZX^G1
MX>7)<'#V8W!\<G'ZC[>'EZ=G;P/X\]WYR8\GYR=OCTXNP@<U[O/3?_QT>3$<
M'+X]#MZ<_GQZ24.^>%!C//OQ00WGXN3\] 27[,E3D<OSDV-H_.SH/Q_4.!_6
M*2.MUV645[.BA%<VRV52QE$%9^J[7\XO?CE\>PF7REEP<7)$Q\[!BP,\>N":
M>?#C/TZRZ"8JD^$ ;E:X5=\$1V?G[\[.^?Q]<_C;@Y^!SZGUNL/^O:GJ=+9J
MZ;S[>T_O6.>]O(+E;J#YLH+W)M,P.(H6RTF29<'K)+Y*RB#*I\%_)M=I'IRG
M\5543JLB#TY/PV!:!/!],EG!&I78V:"^BNJ7]VCV_KHZ],>(QAU+QL$>G(-7
MR2J $P%6-@G>E4F5XLM()"Z2N$SJJ%R% 7R^3.(ZO4XR^*N8!?_58%>3/(#G
MRVB9-'4:PYM.\W@O#*) G3,!*+5+T6N#$;[B[]GT7TWQ/2CX1^8KU.?_7M(7
MX[U[M  [Z?H# W[*TA58ZQRD51 U]551PN^F05W !U63P T<[N_OX_\'%9P_
M\!H0,1#&65*6\+N+NHC?AR23>='^'-N,&_@[K[-54#1U5<,/TWR^$Z0'(DC/
M1)!F1985-["R>!P568,2504W<$$%TP;6/IH6RQK$8K*BPVQ2P$V&@C1-2SB[
MBI*DJFY)9.M0>JT>.E8/V6?3[N9[*$K1;S^=G)\<7H3# :X_:S=I'-4)KGV:
MV]>61VB697$-]V0%[8+V%,195)%PI;5SOE5T/KW/BYL\B*KN@1:#_*8PWGP^
M',#3G5,P#+[<W]O?/PB641E<1QF<E*#'\I<A'9W1)(-]41:+H(;QXH%*_P5-
MKLAA*&6P*&!W5# )276?UG<GO'<GO-TCJWO-SM(/),33%.46[E%RM\,KS <@
M^V%P7=1TOLJW(*#7:#: R*N/^+]T%X/1MD"Q'PY II/%DK8&?I&E_VK2J=HJ
M*/1)'O.E'N6KX.8*#O)5T.1T^4]%/#U7/K\%NITWBPD(/OQ"U /<.75:-]1;
M;)/;& [4$[ Y84FX"S7:,,4L5._G#;WX'IN_1V*SVQ-WLR?2&N5?"4&9J .\
MNT_"8-F4<(B"O8.JJ#F\ZQ6>UQ&<[DD5I6 Q6UM(;01+L,D^JLLT9HT$Q K.
M<Y0ZF)D:=DD%WV<1R2HT%%D"+T:7>RW<7($5CI(.%KI<$?C;@[:"['E8GFW=
M5\/!5<0S8L:G=.\01\J:5;53;Q[*;GA[]EO(@;.3'\_.3\+@]4EP>AF<GUR<
MO?GUY#@D/T[/K@BF!;Q+_#ZBZ9"B@S\GI0-DGL[2-2<W_CZ.JBO008:#Y$-\
M%>5S>HCW196 R9;6:6)N%'@ 7@;Z#6X^.,7M7N#>H\\2O'/2/-E^)P;.1L2K
MRNS$JL%]UG_[?/J-L0L2WR)N<7ER_O,%!1$Y4A,\Z$#-?3_$#NX8J?'+#Q=)
MS+?7 =K@>P%\=)S,TCRES<V?_2CG$ESDRZ*2$P-UO=IQ&+"JRE?J572=M+Y>
M)%$.__U<%V 7#?.)/"OW"P+TJ0:MG3V'LUF:I6#X6#Z>X0"%H2)#X1W<&&0_
M1'4H7B1T,99@7^N_ZJNR:.97CKV=XMY?)-,T*NF& R6N+HN,[KBT4G]F[*KB
MSR@^ ]\L%O!"^<%P<)/65W#-<C](4Z,KBZ49W>M-!8VD;'61352B0<6-G3=9
M$CS??Z%4Q0M]YP:'<?V9O*,[4?],HIZ!T( ]G P'1VA2@("T(R_MXU$.15"0
M:E3G0!)!T.1,#KX9)9\K4G._1(@&_C^>/ E^3)-L^C)X%\V3[Z&)?S6HD,*C
MWP=GY!FI7N*K9/Z^#WY%=QY\'3QY(F#55\>GOZI^MF;A:YR%25'"JNG/7F<1
MZ*@',,55D:53&.CEX>LW)\'1R9LW[PZ/CT_?_N,_OMC_@OZ^>'=XI/Z6-TAK
M,9Q#T;*"GJA_?1_<I-/Z"@>]_S??Q7QYKMJX1K=I'&5J'6 5W87!%<,GCM43
M717)>1W\UII*-8G?!Y>K);S_L(PF:?Q]\#9:)#S1;PN<O@/[H:_44_C-JZ\N
MC_%_SO%_<';@OS#+G@F?E$GT_LDD09/_9;"D1;1E\VL:^CMW?4@\C5R\<UNW
M.X6=Y95^I-ODP0_:1)"B_'W9+.MX-1R<7,/;["/6Z!9R*1L=-,'?PB$QBL:=
M> -&&>"9"Q@1A2GR.KAH)G"*@X:Q@B<LO0"5B2EJR:P8H!( "O23_:>CFS&^
M]#R9-QFW>O'DO\?*.4JJ!WMI(S3<29EATQFL\CA),*(JB@5V9:)'B29W4<[A
MKO@W-0MJ2EFBM0_-@=H437$%\-\4XY@FDQJ?R-)D%LC?Y(F;II6*Z870<?@W
MS$=,ZI'M3H8_JQ26*(*/HQOET?T=%)MJRE:_XVOK3B2ZB'MG4GN*1Q.9&=;7
M>&JF032/H&OU+=='33'YJ7&=<'YA-IRI)8<,O"PO:IR+!4P'O! 50%C%K_>#
M:;1"CV0M6B+VAR=X%-]67E1_,$H JS.EN-=T.%"S7N/S:H%56W1=X'RKM5/B
MP5]$2_(4*6^\&F7@#A+>2(<^@I!&4U^_MUD>:'XV0Z\J_A1>7("^O:!N\QS'
M(' %/$'S@*_(TO?LP4KU<"IHM8;FTRC#Z%JMHG?*!86A%6=!$!<UAQ5! :RC
ME;,V< 4F^11$TEHDF@*K<S#@Y",7"DR2Z#UMS'F2@]Z6@2& T0T:LW+,3>"K
M64KCB&%^4]Y5H]G'"@>,*<-7+I*$-A-V R=(-QZ(<7*=PB&);FW:]20!**%@
MC:=R'.@3 %]-_KDFKF''4JLTZW@*0&_AZ]%\FPX/![Y-.UFQ1,3THEF49DU)
M,5'X) R2#TMX=P4F&UIO*/(5O1O-IH0B *%(,4QP00(>Q7#P)%5,Z@196=:Y
M72;S@B.WL "\/BA[TF_K_(SX6)JYG@IL* $QCG4(J]WR3KU^#(.V](:*C3,5
M<7U7IG'R\?;99&>?/8I!&P&B&R"&&VTX.+N!BZ*Z2I?!&]"6ZC]DZG\--_5.
ME![#H(TH-148$%4U'!Q'*[_] JH.7*EQLJSY<H[@1H?/0OX+# 7U;_PA1Z51
MWPQFR914F"R9P_]>H>LBPBN9Y/"7/*TI_$:WL]S[\#U<LKDT@GHIJ9(* ()Q
M/GF<GL-[%,?\SZ)\3SY2"PE#^@?<Z26[7LF"4-?TO("#EW0J5+!8]$%WB#.X
MK'?B_Q@&;8G_ZLEI[@0%;G=@QN-1>KT[-!_%H$T^ V$<R,MQQ &<X!)3D/@L
MZ9ZB*$=%S-!UL"_8;"38$IYB8H89R!KZA<"D)9N$3:N>1\@,0FN>L'T-6C.E
M'+<P!8C]@;^EV_.R:):J6^A'FH*Y4Z83XSP*#IY-G[P ;7)T,$;K>-%D<W07
MB"\(7WZBX!V'<3VV[)IKF P)906CFZN$CED5+^,.H:-!JRU!H;46,D"7*1[%
M#*+M@G#)WJ/FQ>"C8_PFK9(Q8WCI>JH8H/CLN[^I)@3B:! H7E1X(9V%&8?7
M\(*1ETRKY_#&Y$-2QBG;<A<,(R$(@A_%"$:K>:= '^MBSM-"QC1'Z?K:&6NW
ME-/515+.L<$<+BL$W10YQ0/H!F43'>6'7B)Q1#)9K?CFQA;:KX0!A2)\\Y2<
M/KSB&E-3&[GG2#PM(ESVF(0F\XVVCI48LJ!X:9UDB#E*T5;NMH4" H)35;PP
M7Q_H18WF<[":<1/(\BZ+&W97>9P)U*$F1N$@=))LBEGW?3[?6I5D',GE_$+R
M0V4DR99/";,1LDRY-T8H =;?VGE!T6%T'L!^1< A06-!?J,*+I:*7!>YO70:
M$.N9S^ .II,.K\WS26<0^6]D[NS7F4/)D0)T]T6@?2VSB#V70513T)P ZT6I
MW&D1?C@<K)*H1+![6A XC<+JU$OX]@G<Q3/5ET6"T& ]"1XXFU8^T9/''AY6
M_R*X0WYG-"0]C5X9<VKB@P4L2[G-.QAE')R5*=Q)<&B=4EK3,4[@",^XE;]Y
MTD^KI&3':=7W(E##[3>Q4@Q-WU";>;%(%=*YZ)T$%*\U8]]BD,.!ZK'^:>^H
MQ^S,$X\GG),Q:>HJ->?(3:_ :PWDC<4"QN %L;+Y@+[:%1U@$VU6D)MV4C1X
M*C%>$:=SIAS7/!X.K[@*6YQ%#6*&..3"]Q+)Z02F::>]/89!6]FH"XRYN)J:
M @-U;5/K*L<S6:M IIF=_#R&03OR@UA%4M7\RKYUF/V]K/#+2B&^*D;^FSPO
ME?AETKU0S+0N;'0ZG7MF*;2HR>%I36D$C''6WRVB%1D*?$U/$KB2J8ETEK*#
MA 5YNA/?QS!HO_@&)Z#?76-0LZ[\WK_UUI/HV+::*W?U3=%D4]8:,_:DL!*K
MPXX4K2,/':A>[%HD!9'[IS)DTCS.&KSE0U(;BZ8.,NWG%K<C 0V6VH22':9R
M!@K&9,'S%+?D_ />42G!*%D7N8IJL*2KP.X*VX!UBJF7RF822Y#2,>E/WD6<
MGEF4H6.?JO%7/1, .S(!XSET!KW;CX]AT-9^5(Z&X>!P ;JM!T;$=NQ"XWMK
M\LL0L# @[ )HXSNQ>0R#]HK-L0MLOV7,+]JYK[>!]S[=(7GO$,G[=(?DO?<[
MXL$/VGN8_B$PSM<[,,XC&;17=BXH8[^COX5T4!M6-5+G='*_K?NK:!&Z #3K
M2[/D3#$=CYJU6O!%DI2!AX[V.(:+@W*Y=9"'$\O8$MD)[&,8M!;8XQ3!]QBR
M/944_QWT<"<\'RT\P=NBWL%7=S*TO0RI$,IP<!CW.#NLH(N-.2%RG.^>/:<$
M:; HH*_34(?*RR:3($VI4Y\J!\E"KC>"L^Q$[C$,VA(Y9"WSWWA&ZFS*&XP4
M]^AHZ.%EIS+Z<*'AK%@EV(]B-H.3L"0/\SHJRN' 9J,B+[O;<+#,HKQ#==F-
MY.=%_D2]?QOL@J<G1&NX!B% *3Z+M*X3FA;GC6:,256#JII65]#362$Y49+_
MPF"FJH.(LN: @4JDYPJ*0-!6QL$NB3JN&MP*4$C#."3XUZ+U#CP9OM*^?^LQ
MRZ5/_6C[],U[K5# 9OW=(JA5^(FIH):)SZLIX34PR$,%B%"8!E3>*2>M'=&C
M&Q6Q+9,DR=7Y%U0IBNSFYHD(+(_+!#^M7:Z]UHL8131-^,=,/J@798D&<F@6
MAOYNK8U\9F5"=EJ'G9_(P4W9K)YNC%(<*J&/5$J7XC>OBV+*F92JEQH;[G84
MV]61GY'$IC#=\];+,[:EB><$,P@UM@7^%5\EM94.EM?I-.5,5U[:B@\-"0!Q
M9ZPO_.O;PGZV^@>7J%[@:4%/:\K$!/$V<@A2:_2K;>5%4>%RXNG:_6MC52O:
M0U6-J7'S-+:Q89N 25-H@I)&*SSQUIV@?.FK[<*"H$5-'>,*RUWD<(Y..#]0
MP>M&+(0D+]#U>F5![-2/QAI0%B*8+\EF'.]D^!#"^RH'WH>8-18($"E,C.1L
M6DQT9<"K0D AYH\,\V BZ1=!M8+OYT@1&QLC77_KB;P22("&IXC;/$G0T71*
M:Q)E*FNT0KBP_EP]D\+&K71F[0RV& QGTM3R!A0J#L2"1#FXPC3OAW#A,K3P
MM[ C035(<1M[DB3+"-=_KO' O$0P88(]9! <M[$RDX.OHOYSLHCUOIV2]Q@&
MK96\'S$7B=-ZAH,>0/Z.^68G0FM$Z!^'A^\\J$ 7$2BY^:B<QY@6AW=T'&/D
MGO#3)1R5Z3+;'3^/8]!:=GXB#6*;7+)Y>@WZG47D8LZ<ISNA>0R#UD+SOYL\
M1171.+SZ$*66D:F33,C,<+ZR\'Q>O)Y)=N(T!4LY(T6.TR# W,K2.$76PRK!
M#J(N!KU=@O(6+-&XQEXJ[7%-0A1(=HN(ODWS8RA]=Y+_& :M)?]-FN25CXX3
MQ".!AIB&)U02N@J4:1B"/1 WBTF)-I[@/,EL2<NJ#D"<FBK*"!!*E0JN$_43
M99=;Q-$[F7L,@[9D3A\\'YWS_6)7;>I!R@8\,QP0E<11T90N'/XV\G%PL&-1
M>22#-K)#(7!%""!.\+\@(G=WQORY<J+R9SD0R0FT?GW?=LVS8N/4XT!7MU,=
M9HT.CNG=Y32S_,@Z\#,<F-1V:1;3;M.X0=K-]0 SRQ99\P:[X)I*#<+$M$EB
MB!&&@X1,A#AAF[C_;;MC=0N@^K,=4/T.@>K/=D#U>[\C'OR@]07"@4EO$0N+
M<8*#\5:P% ]U(=P)@[ILT(@VI2\9,M'DSB=1515Q*L__CMRV ?(J-)B@3!F8
M"5;_@SV3I4C3(.%.]5/&L^@/#>,:!5Z)!4)Q/E?-!/M=6?7[QL96-Y0M>#F]
MAS'N[H#',&@C\5V<PT;(H ]:,V4YSX.W((NDG!Q\&P9/]Y\BF'!1@#*^IM Y
M5UV!"RE*$;Q%FW!4C8G8A1.=)PD(.ROWA2))X8# +@ST* :M!59X^)\_[XHI
MLZP]?^Y@4C51CJ(3<8 U+<D^1'YK502 FA-E6H&%[ K!H-W#/T)-A"YL^@B3
M97Y,71_ T$2T*FM;O0+CE4Q6A_J*\E#@W8H6S.[:3NX?PZ!;<O_\:9_<PS=_
MHMQ3J2X0X&694(6#3J7L3[,-%)H)[PO>$D3WMML3CVK0>D]XH[HVU=1F+DG+
MH1AP>N%.AA[#H#TRM%V^C$F3>;9+D]G)VBUEK60YZYY''QO-V &:'L6@C0CA
M'34<'"=9"M?6JA/BN"V]^DY\'L.@C?C47*&,(A@??>;0Q:>5<A5ODMPG-W-%
M/?-L)VB/8=!&T'19L9Z2T#KI1#BEF;Y?RD);EJ+D*=G%HDU>T,J;NT09DD60
M%<P%S6EOYA$N:PA*V56Z9&]C6M4[M?]1#-J23TU;?T*2N,MBV<G.EK)S6493
M*ECHK^E$A9H*.W-/<E:B+)!'@Y^C\GU"=.O%,N&2ABKA;B=,CV'076%BD=BR
MQO&"?ES9&?R5*W.MM/D@2RN)1$/;M? (U"*.5H(V);#^J\%\SP)A(?#QVW]>
MG 2'"QA*C$.CCZ)J&OTK.))44NZ[\]4_LF*R]IN+!"F[W!\D4FV,>@TGL\J!
M'^EBLW)J5XK9H5WK<W<6/XI!V]M'Y:'">5S$1#?M3?*!/7!DP'+$W)%@\=_(
M%-?QD#J,5!8[TBG4P21E1@/BTM UE[A(MJN&CL/A +6(Y,-5.L%D=LHHCZ^2
M:2.$U64";7]\^SM!?PR#=@5]EI0(U.@%:8@1I2LJ$0ZH[B5X<([4S0_M).XQ
M#%I+W*]1F3)ISSD>F&M+\&U)6S%*QXQ+)LV%"X"I&@.DRQ!7B)TUR=0CI5,L
M %44)!QRB(1:M0-4K0#%JT&1&<I3L^L"6 0>/81#24HXN='AF$H76"0\PX%F
MZG$)<2Q2);=^.7]/(\(Z2^0KPX->4R==2X4'>"=?2$H_HR<KX6A"_4VB2C.T
M7]?0G=K5%@S/39JG&%AW(._D).E?!JQ!]7JL*M6;23"C=ZB=6D.MFLGO4M6.
M^8:@KPG5+:L0U35K$/?(F/R/[B7YC7 VA3K(U(/$YY9);.JR%,0D@&><U+)B
MMQ*[GI23*1-'$4'H>^AB% 4->PG8I!/B%2S*YW*:C5(0?H)-<UT9$D\&,;3W
M#\4&N?I&9"!V5JT.Y(Y!UAB%%&7Z+34C&723<@/*!,0[Q (VH&P8K 7U&KVV
MM!7M92815\N18/(\-#7EU=R=_ELD!SS?)0?<87+ \UURP+W?$0]^T$8?^LU'
M7A/J^HAX?X7*WQ<[!ZB<O9QIUG'FJ.J)K.LLEQD<Q2^)(3/5-XWCRX'/<G'H
MT+4K'AUD)&MY&$/QZ\#0@^LB ^LXN$E0#<(4!-CET=SB\>N\2E--3E7]34H^
M2U#7J)$!($[H7?CUF$K+X_<M'^=:KY0U$LLU%558W[0H!2+X.BL*A)3/@S=[
M[_:"$6M.SFB/X38C3.)W+Y_M@^&]MX#?:7?2$=Z*J 2-\2Y__G+_:;#L^X44
M!X:9/[L\^J_7V"O\QW_KNJ?>&>Z96]$1__CDXFA;_>$ZI!D<TZ#O,HE@C[A
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MU!E.-?;E>B/ZUSR-I"7T>(MIQ?\D?M3R92(/&D6>:)]LI6=:"R U>^@>5CU
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MJ6H+:#+IB41' 5@WUU(+@P\=EQB$.SW6RJU5;4W"K)N'PZF_,)[ :9H_V6J
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M5Z_/CO^)F^*KGRY_?O/#_P=02P,$%     @ 2(%U67<LRQYF00  \](!  D
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M:"G[2JGDU,]F#ECG21\L<X4OH;:P4?Y!E9@VB!F$(^EK.QS,XX]J)A^/J<H
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M!])^Z -I.PRD_= 'TNYN(.VKJ1??[4E#VYE:I(;1]EK&WT7+^!RM\;S6Q6Y
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M2/CVC?+(YMT/UFX^YLI_F=T/MMA\WI7M=M_\0O:9$C7UW$:X1^1#M]WT]!&
M:I"7*Z>1GL N)PD["I*5>$@Z'H7C<;OP(?U&<5KPC<?R.*1IIT]J&$R3*%[
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M ^;1Y@:UZ<>FO',1?8P7U<*_E UG#;5JYXPXQ^VB>\Y;.-5Z_EA#DNNRJBY
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M7<:XP)HRMD:I&WC!>S)%]8[*'H6'\Y?(+]J<*R88:Y+0UMB,E,"JY\Q]JAM
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MB-_I/GZF3NR#(WRPH_ZVN[.[^U0M_52=^U&AB1V!#ITNJ)>+>1C,%<KO3.=
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M]0^ CO^<>B-> \(WPK/O3[J#C]L$<>PB0>\50GJ/!S"#'Z'CGG?"SA)I35Z
M*3GLCBL#4["D.(W82;]<NE&WO\\#0!I@ODX'1]YH1!,+W[5;WE'_75]Z@"6@
M[T].AZ/3+LP0?#<\A=^>OGB!#9B_N[7&=[#G#_WQ(<SM /TY1"MB-]\=PZ?.
MNB6'ODZ.O/UW0&D?5J5W/!C@<L% L"&8C#V8!'70W_?@\>$[G)\>3BV-Y!C!
MH>KH&&=^" \-N@-T&ZGN<(C):;2ZU)_A=[?[1IGXJD[C9XU_^)OZAY\U_N'&
M/WS_Q<^WLF6T0<XLDG,"KBHV:\1+[*1$96#]AT!#L $)*MH]^C,GNM3H&>=
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M\07C/F%#F)9XXC$SUW?)K)(NSBCI<Q&OUF4PFZZM>Y].>>'(9NV1_B!M+=/
M;S/6V-\U8?0^M.V9=#(!:)F3U.;%0IHV3P"7J9ZZ0]9O,UAGVUF",ZV4_,N
M/70+9H5-5\(FTV!-UK4X;A#XF(%,E[71I]*WH7\]JG\J/MHS*!;G4W#)N3/5
M3P'2@3D::#N/#EC@6P;@UG",_*L3JK7Z&"BC(4E05W@1*0CEA ^8@;DUDUC
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MFJLT.5!@'[L&M<][KG-K7NYZ^Y*U^-EXX!F/!SVQIS0[;Z9:KNBY;9CN5:J
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MW1\Q6#:)(,8QM6C4+&X2X_Y><K)I]$!#@RX4?AADP5JSJ2PXYLP;XF4R8$O
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M.K'<?XO:TENIWP18R3E5=<]X2F^E!.Y2 O'=X.@8 JPH9"/!,Y?1O26W%++
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M1.)MG@C-HZ'E P&^;PTD_@OJ@X=#(Q+RP81R;O,V(D!G>9$]$/NOF-C=.E\
M^.M'>W\WMQ8X^XTB0/QO7@K^/;5($>A3Q61D;ND*P'[/&$C]%).Z0R$J[VL1
M06FO3<'Y#S[L'7E(J+M,AX3G'G7-,>W'76 .18Z2<Y;*1,7^)R4*#'W#&(H<
M)0TMD5@Q\$ZJU)8SWE[%;0U%CI* EHFLF/FU2%BRL(-NG])X^/3B=)OUOA64
M,4K2Z1*%PG;UID$D=BS1QW?7$LH8)=?TB4/AW#%Z%.$]$='Y![KP@=XSA9)&
MR3&]\E!0]Q6+B5H,6%C>:>S;0F&C9)9^@2BT[\F\%QE5;,3RT?ARZ,XB4/8H
M:25(+DH(>B*4:BHW7A=W9&JNQT5'1MXNO:0@-!PH^>8SI*,$I1U%!I=>_KEA
M@C9]H2@T!X\1X07 (_.%8&\]#WL+CATE#RV5^4*PGSP/^PD<.THN6BH3$WO'
M?+Q5]W+F&(%V&D.1H^2B)1(Q@6=WFEO55_*1Y9,2RZCOE8"B1TQ1_6)13_C\
M)@\YVU>64-Z(Z6JQ.$S.?:D3PO]BT[(GR6)[*'/$Q-4GM.H7C'G<[4L+UU2B
M'1,H7Y1<M5!.U4AMA!4E[M-WVP(*%"4!+1)3,<\;:<<^)E)XW\?N6T&YHF22
M+E%5=[QV&K%V7OH;7X-GL*%TJ[LR*L;X5;'$>-"1<9R*Y3L:QZB8PQ2*%R7]
M\\JK&/4@FT6?,#'^:)X0%2.\F'.1'10R2K+G%E8QX;ZB-M+4/'9G\[CL.@-U
M.QJY>EZ?/90X2JY7+A27?$_KE*KG\B\H!8T"2MH'%5UU/T/#U'1[BV9K>&]7
MS#AZF3TK*&N4E,\EJF*VG^1R2=1@$0\E=R\/*32$$D9)\#S2*H:\Y4<QWAT3
M*%B4S*Y0#E*?<#T/)W8EHGOV0K$E%#!*IN<3A];WCD%][_B9?2]*QN<2A<0V
MGQMNKJC;(6=CXEY)YBT 7F>#2=PCM>KU>]F2'[N-@HHS/[KF0S%VARD4.,X2
M29^\JE&G$4MHE+O498*(T*14ZW5MCNR\O!0T #AK*(&B45[O?Z6<?Q!R)@:4
M:"EHE#_J^][P.XM HX XAE@B%R4$7R1/#2653015CFO 80I%CCAVZ)"',_<R
MG]2\OO?D^^7XB+M*0,$C#B+ZQ2+-3TNH]9D]TBN2D*6'/OZN$E#^B .*?K%H
M\^=5Q]QXQM(_9KYC"*6-.!6V4!H*Y$%,.+],-1-4>_N6'4,H9,0YKX724"!?
MQU2-3:?V7LE9,EFN[?3!=A2 0D><V>J5B@-__K2./%__YB5?8 W>G0 1NU,D
MUK8;86@G4N1W<A$1Y:#NLX=R1UU8Z19:,?G;9$+5YO-3YDS/Y&V^20_EI:!1
M0$E7H:)Q[JT;*_F]M]8M.RAOQ,2T2!C.FJETR%G8Y9)XG\NWS*!\$;/0 EDH
M>"^)>%#I- D7=L=!2NWPB5Y?;8"$"%@!-"2(^>FS4."\+I!Q;!<3R?!A,#&B
M]6V:9-L'&_^\+PV\Y:"AP5S$"1".]!2DGQ9ZT>AR<4='5-EI"O=TGER:AA[\
M#T6 XM#XH.XH!,90$*;SQIZN&W/@0/N<@K8C/M2FJO^WQ@JV.?Z^#3JV*?X/
M-NK;UABWY>7U:G_9K<G-D7\ 4$L! A0#%     @ 2(%U6;\CU3UCA0  4< "
M  D              ( !     &5X,RTQ+FAT;5!+ 0(4 Q0    ( $B!=5D#
M1S05&E8  *M  @ )              "  8J%  !E>#,M,BYH=&U02P$"% ,4
M    " !(@759=RS+'F9!  #ST@$ "0              @ '+VP  97@S+3,N
M:'1M4$L! A0#%     @ 2(%U6;86YML;)@  )  !  D              ( !
M6!T! &5X,RTT+FAT;5!+ 0(4 Q0    ( $B!=5D 4VGH,QT  +32   +
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3!@     (  @ V@$  (IW 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="qlgn-20241118.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-18" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-18" id="Fact000004">0001460702</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-18" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-18" id="Fact000010">2024-11-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-18" id="Fact000011">Qualigen Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-18" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-18" id="Fact000013">001-37428</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-18" id="Fact000014">26-3474527</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-18" id="Fact000015">5857 Owens Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-11-18" id="Fact000016">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-18" id="Fact000017">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-18" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-18" id="Fact000019">92008</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-18" id="Fact000020">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-18" id="Fact000021">452-8111</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-18" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-18" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-18" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-18" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-18" id="Fact000026">Common     Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-18" id="Fact000027">QLGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-11-18" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-18" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
